Document:

EX-4.2

 Exhibit 4.2 

OCULAR THERAPEUTIX, INC. 
 FOURTH
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 May 31, 2013 

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
	 1. Certain Definitions
	  	 	1	  
		
	 2. Registration Rights
	  	 	5	  
	 2.1 Required Registrations
	  	 	5	  
	 2.2 Incidental Registration
	  	 	7	  
	 2.3 Registration Procedures
	  	 	8	  
	 2.4 Allocation of Expenses
	  	 	9	  
	 2.5 Indemnification and Contribution
	  	 	10	  
	 2.6 Other Matters with Respect to Underwritten Offerings
	  	 	12	  
	 2.7 Information by Holder
	  	 	12	  
	 2.8 “Lock-Up” Agreement; Confidentiality of Notices
	  	 	12	  
	 2.9 Rule 144 Requirements
	  	 	13	  
	 2.10 Limitations on Subsequent Registration Rights
	  	 	14	  
	 2.11 Termination
	  	 	14	  
		
	 3. Right of First Refusal
	  	 	14	  
	 3.1 Rights of Investors to Acquire Offered Securities
	  	 	14	  
	 3.2 Termination
	  	 	16	  
		
	 4. Covenants
	  	 	16	  
	 4.1 Affirmative and Negative Covenants
	  	 	16	  
	 4.2 Inspection
	  	 	18	  
	 4.3 Financial Statements and Other Information
	  	 	18	  
	 4.4 Observer Rights
	  	 	19	  
	 4.5 Termination of Covenants
	  	 	19	  
		
	 5. Confidentiality
	  	 	19	  
		
	 6. Transfers of Rights; Calculation of Share Numbers
	  	 	19	  
	 6.1 Transfer of Rights
	  	 	20	  
	 6.2 Calculation of Share Numbers
	  	 	20	  
		
	 7. General
	  	 	20	  
	 7.1 Severability
	  	 	20	  
	 7.2 Specific Performance
	  	 	20	  
	 7.3 Governing Law
	  	 	20	  
	 7.4 Notices
	  	 	20	  
	 7.5 Termination of Prior Agreement; Complete Agreement
	  	 	21	  
	 7.6 Amendments and Waivers
	  	 	21	  
	 7.7 Pronouns
	  	 	22	  
	 7.8 Counterparts; Facsimile Signatures
	  	 	22	  
	 7.9 Section Headings and References
	  	 	22	  

 OCULAR THERAPEUTIX, INC. 

FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

This Fourth Amended and Restated Investor Rights Agreement (this “Agreement”) dated as of May 31, 2013 is entered into by and
among Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), Incept, LLC and Amarpreet Sawhney and Farhad Khosravi (each, a “Founder” and collectively, the “Founders”) and the individuals and entities listed
on Exhibit A attached hereto (individually, an “Investor” and collectively, the “Investors”). 
 Recitals

 WHEREAS, the Company and certain of the Investors entered into that certain Third Amended and Restated Investor Rights Agreement
dated as of February 1, 2011 (the “Prior Agreement”); 
 WHEREAS, the Company and certain of the Investors have entered into
a Series D-1 Preferred Stock Purchase Agreement of even date herewith for the purchase of shares of the Company’s Series D-1 Preferred Stock, $0.001 par value per share (the “Series D-1 Preferred Stock”) by such Investors (the
“Purchase Agreement”); and 
 WHEREAS, the Company and the Investors party to the Prior Agreement wish to amend and restate the
Prior Agreement to conform to the terms of the new investment. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants
contained in this Agreement, the parties hereto agree as follows: 
 1. Certain Definitions. 

As used in this Agreement, the following terms shall have the following respective meanings: 

“Affiliated Party” means, with respect to any Investor, any person or entity which, directly or indirectly, controls, is
controlled by or is under common control with such Investor, including, without limitation, any general partner, managing member, officer or director of such Investor and any venture capital fund now or hereafter existing which is controlled by one
or more general partners or managing members of, or shares the same management company as, such Investor. 
 “Available
Undersubscription Amount” means the difference between the total of all of the Basic Amounts available for purchase by Qualified Investors pursuant to Section 3.1 and the Basic Amounts subscribed for pursuant to Section 3.1. 

“Basic Amount” means, with respect to a Qualified Investor, its pro rata portion of the Offered Securities determined by
multiplying the number of Offered Securities by a fraction, the numerator of which is the aggregate number of shares of Common Stock issued or 

 
issuable upon conversion of all Shares then held by such Qualified Investor and the denominator of which is the total number of shares of Common Stock then outstanding (giving effect to the
conversion into Common Stock of all outstanding shares of convertible preferred stock and to the issuance of all shares of Common Stock reserved for issuance under employee stock plans of the Company.) 

“Commission” means the Securities and Exchange Commission, or any other federal agency at the time administering the
Securities Act. 
 “Common Stock” means the common stock, $0.0001 par value per share, of the Company. 

“Company” has the meaning ascribed to it in the introductory paragraph hereto. 

“Company Subsidiary” means any corporation, partnership, trust, limited liability company or other non-corporate business
enterprise in which the Company (or another Company Subsidiary) holds stock or other ownership interests representing (a) more than 50% of the voting power of all outstanding stock or ownership interests of such entity or (b) the right to
receive more than 50% of the net assets of such entity available for distribution to the holders of outstanding stock or ownership interests upon a liquidation or dissolution of such entity. 

“Confidential Information” means any information that is labeled as confidential, proprietary or secret which an Investor
obtains from the Company pursuant to financial statements, reports and other materials provided by the Company to such Investor pursuant to this Agreement or pursuant to visitation or inspection rights granted hereunder, provided that the following
shall not be deemed Confidential Information: information that (a) is known or becomes known to the public in general (other than as a result of a breach by the Investor of its confidentiality obligations, (b) is or has been independently
developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third
party may have to the Company. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor
federal statute, and the rules and regulations of the Commission issued under such Act, as they each may, from time to time, be in effect. 

“Holder” means any Investor (and any persons or entities to whom the rights granted to the Investors under this Agreement are
transferred by the Investors, their successors or permitted assigns pursuant to Section 6.1) or any Founder. 
 “Indemnified
Party” means a party entitled to indemnification pursuant to Section 2.5. 
 “Indemnifying Party” means a
party obligated to provide indemnification pursuant to Section 2.5. 

  
 2 

 “Initial Public Offering” means the initial underwritten public offering of
shares of Common Stock pursuant to an effective Registration Statement, at a price of at least $12.00 per share (subject to appropriate adjustment for stock splits, stock dividends, combinations and other similar recapitalizations affecting such
shares), resulting in at least Thirty Million Dollars ($30,000,000) of proceeds to the Corporation (net of the underwriting discounts or commissions and offering expenses). 

“Initiating Holders” means the Investors initiating a request for registration pursuant to Section 2.1(a). 

“Investor” has the meaning ascribed to it in the introductory paragraph hereto. 

“Major Investor” means any Investor that, individually or together with such Investor’s Affiliated Parties, holds a
minimum of 200,000 shares and at least 20% of the Preferred Stock originally purchased by such Investor from the Company (as adjusted for any stock split, stock dividend, combination, or other recapitalization or similar events occurring after the
date hereof). 
 “Notice of Acceptance” means a written notice from a Investor to the Company containing the information
specified in Section 3.1(b). 
 “Offer” means a written notice of any proposed or intended issuance, sale or exchange
of Offered Securities containing the information specified in Section 3.1(a). 
 “Offered Securities” means
(a) any shares of its Common Stock, (b) any other equity securities of the Company, including, without limitation, shares of preferred stock, (c) any option, warrant or other right to subscribe for, purchase or otherwise acquire any
equity securities of the Company, or (d) any debt securities convertible into capital stock of the Company. 
 “Other
Holders” means holders of securities of the Company (other than Holders) who are entitled, by contract with the Company, to have securities included in a Registration Statement. 

“Preferred Stock” means shares of the Company’s Series A Preferred Stock, $0.001 par value per share (the “Series A
Preferred Stock”), Series B Preferred Stock, $0.001 par value per share (the “Series B Preferred Stock”), Series C Preferred Stock, $0.001 par value per share (the “Series C Preferred Stock”), Series D Preferred Stock,
$0.001 par value per share (the “Series D Preferred Stock”), and Series D-1 Preferred Stock. 
 “Prospectus”
means the prospectus included in any Registration Statement, as amended or supplemented by an amendment or prospectus supplement, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by
reference in such Prospectus. 
 “Qualified Investor” means an Investor that is an “accredited investor” within
the meaning of Rule 501(a) under the Securities Act. 

  
 3 

 “Refused Securities” means those Offered Securities as to which a Notice of
Acceptance has not been given by the Qualified Investors pursuant to Section 3.1. 
 “Registrable Shares” means
(a) the shares of Common Stock issued or issuable upon conversion of the shares of Preferred Stock, (b) any shares of Common Stock, and any shares of Common Stock issued or issuable upon the conversion or exercise of any other securities,
held by an Investor after the date hereof (but not, for avoidance of doubt, any shares of Common Stock held by any Founder, whether held on the date hereof or subsequently acquired, and (c) any other shares of Common Stock issued in respect of
such shares (because of stock splits, stock dividends, reclassifications, recapitalizations or similar events); provided, however, that shares of Common Stock which are Registrable Shares shall cease to be Registrable Shares
(i) upon any sale of such Registrable Shares pursuant to a Registration Statement or Rule 144 under the Securities Act or (ii) upon any sale of such Registrable Shares in any manner to a person or entity which is not entitled,
pursuant to Section 6, to the rights under this Agreement or (iii) at such time, following an Initial Public Offering, as such Registrable Shares become eligible for sale pursuant to Rule 144(b)(1) under the Securities Act. Wherever
reference is made in this Agreement to a request or consent of holders of a certain percentage of Registrable Shares, the determination of such percentage shall include shares of Common Stock issuable upon conversion of the shares of Preferred Stock
even if such conversion has not been effected. 
 “Registration Expenses” means all expenses incurred by the Company in
complying with the provisions of Section 2, including, without limitation, all registration and filing fees, exchange listing fees, printing expenses, fees and expenses of counsel for the Company and the fees and expenses of one counsel
selected by the selling Holders to represent the selling Holders, state Blue Sky fees and expenses, and the expense of any special audits incident to or required by any such registration, but excluding underwriting discounts, selling commissions and
the fees and expenses of selling Holders’ own counsel (other than the counsel selected to represent all selling Holders). 

“Registration Statement” means a registration statement filed by the Company with the Commission for a public offering and
sale of securities of the Company (other than a registration statement on Form S-8 or Form S-4, or their successors, or any other form for a similar limited purpose, or
any registration statement covering only securities proposed to be issued in exchange for securities or assets of another corporation). 

“Securities Act” means the Securities Act of 1933, as amended, or any successor federal statute, and the rules and
regulations of the Commission issued under such Act, as they each may, from time to time, be in effect. 
 “Shares” means
shares of Common Stock, Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series D-1 Preferred Stock. 

“Undersubscription Amount” means, with respect to a Qualified Investor, any additional portion of the Offered Securities
attributable to the Basic Amounts of other Qualified Investors as such Qualified Investor indicates it will purchase or acquire should the other Qualified Investors subscribe for less than their Basic Amounts. 

  
 4 

 2. Registration Rights. 

2.1 Required Registrations. 

(a) If at any time following the earlier of (i) five (5) years after the date of this Agreement or (ii) six months after the
closing of the Initial Public Offering, an Investor or Investors holding in the aggregate at least 50% of the Registrable Shares then outstanding may request, in writing, that the Company effect the registration on
Form S-1 (or any successor form) of Registrable Shares owned by such Investor or Investors having an aggregate value of at least $10,000,000 (based on the market price or fair value on the date of such
request), then the Company shall (i) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and
in any event within ninety (90) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Shares that the Initiating Holders requested to be
registered and any additional Registrable Shares requested to be included in such registration by any other Holder, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given,
and in each case, subject to the limitations of Section 2.1(c) and Section 2.1(e). 
 (b) If at any time after the Company becomes
eligible to file a Registration Statement on Form S-3 (or any successor form relating to secondary offerings), an Investor or Investors holding Registrable Shares may request, in writing, that the Company
effect the registration on Form S-3 (or such successor form), of Registrable Shares having an aggregate value of at least $1,000,000 (based on the public market price on the date of such request), then
the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days
after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Shares requested to be included in such registration by any other Holders, as specified by
notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.1(e). 

(c) If the Initiating Holders intend to distribute the Registrable Shares covered by their request by means of an underwriting, they shall so
advise the Company as a part of their request made pursuant to Sections 2.1(a) or (b) and the Company shall include such information in the Demand Notice. In such event, (i) the right of any other Holder to include its Registrable Shares
in such registration pursuant to Sections 2.1(a) or (b), shall be conditioned upon such other Holder’s participation in such underwriting on the terms set forth herein, and (ii) all Holders including Registrable Shares in such registration
shall enter into an underwriting agreement upon customary terms with the underwriter or underwriters managing the offering; provided that such underwriting agreement shall not provide for indemnification or contribution obligations on the part of
the Holders materially greater than the obligations of 

  
 5 

 
the Holders pursuant to Section 2.5. The Initiating Holders shall have the right to select the managing underwriter(s) for any underwritten offering requested pursuant to Sections 2.1(a) or
(b), subject to the approval of the Company, which approval will not be unreasonably withheld, conditioned or delayed. If any Holder who has requested inclusion of its Registrable Shares in such registration as provided above disapproves of the
terms of the underwriting, such Holder may elect, by written notice to the Company, to withdraw its Registrable Shares from such Registration Statement and underwriting. If the Company desires that any officers or directors of the Company holding
securities of the Company be included in any registration for an underwritten offering requested pursuant to Section 2.1 or if Other Holders request such inclusion, the Company may include the securities of such officers, directors and Other
Holders in such registration and underwriting on the terms set forth herein applicable to the Holders. If the managing underwriter advises the Company in writing that marketing factors require a limitation on the number of shares to be underwritten,
the shares held by officers or directors of the Company and by Other Holders (other than Registrable Shares) shall be excluded from such Registration Statement and underwriting to the extent deemed advisable by the managing underwriter, and if a
further reduction of the number of shares is required, the number of shares that may be included in such Registration Statement and underwriting shall be allocated among all Holders requesting registration in proportion, as nearly as practicable, to
the respective number of Registrable Shares held by them on the date of the request for registration made by the Initiating Holders pursuant to Section 2.1(a) or (b), as the case may be. If any such Holder would thus be entitled to include more
shares than such Holder requested to be registered, the excess shall be allocated among other participating Holders pro rata in the manner described in the preceding sentence. If the managing underwriter has not limited the number of Registrable
Shares or other securities to be underwritten, the Company may include securities for its own account in such registration if the managing underwriter so agrees and if the number of Registrable Shares and other securities which would otherwise have
been included in such registration and underwriting will not thereby be limited. 
 (d) The Company shall not be required to effect more
than two (2) registrations pursuant to Section 2.1(a). In addition, the Company shall not be required to effect any registration within six months after the effective date of the Registration Statement relating to the Initial Public
Offering. For purposes of this Section 2.1(d), a Registration Statement shall not be counted until such time as such Registration Statement has been declared effective by the Commission (unless the Initiating Holders withdraw their request for
such registration (other than as a result of information concerning the business or financial condition of the Company which is made known to the Holders after the date on which such registration was requested) and elect not to pay the Registration
Expenses therefor pursuant to Section 2.4). For purposes of this Section 2.1(d), a Registration Statement shall not be counted if, as a result of an exercise of the underwriter’s cut-back provisions, less than 50% of the total number
of Registrable Shares that Holders have requested to be included in such Registration Statement are so included. 
 (e) If at the time of
any request to register Registrable Shares by Initiating Holders pursuant to this Section 2.1, the Company is engaged or has plans to engage within 30 days of the time of the request in a registered public offering of securities for its own
account or is engaged in any other activity which, in the good faith determination of the Company’s Board of Directors (the “Board of Directors”), would be adversely affected by the 

  
 6 

 
requested registration, then the Company may at its option direct that such request be delayed for a period not in excess of 30 days from the date of such request, such right to delay a request
to be exercised by the Company not more than once in any 12-month period. 
 2.2 Incidental Registration. 

(a) Whenever the Company proposes to file a Registration Statement covering shares of Common Stock (other than a Registration Statement
relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; a registration on any form that does not include substantially the same information as would be required to
be included in a registration statement covering the sale of the Registrable Securities; or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered) at
any time and from time to time, it will, prior to such filing, give written notice to all Holders of its intention to do so. Upon the written request of a Holder or Holders given within 20 days after the Company provides such notice (which request
shall state the intended method of disposition of such Registrable Shares), the Company shall use its best efforts to cause all Registrable Shares, and any other shares of Common Stock held by such Holder on the date hereof, which the Company has
been requested by such Holder or Holders to register to be registered under the Securities Act to the extent necessary to permit their sale or other disposition in accordance with the intended methods of distribution specified in the request of such
Holder or Holders; provided that the Company shall have the right to postpone or withdraw any registration effected pursuant to this Section 2.2 without obligation to any Holder. 

(b) If the registration for which the Company gives notice pursuant to Section 2.2(a) is a registered public offering involving an
underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 2.2(a). In such event, (i) the right of any Holder to include its Registrable Shares in such registration pursuant to this
Section 2.2 shall be conditioned upon such Holder’s participation in such underwriting on the terms set forth herein and (ii) all Holders including Registrable Shares in such registration shall enter into an underwriting agreement
upon customary terms with the underwriter or underwriters selected for the underwriting by the Company. If any Holder who has requested inclusion of its Registrable Shares in such registration as provided above disapproves of the terms of the
underwriting, such person may elect, by written notice to the Company, to withdraw its shares from such Registration Statement and underwriting. If the managing underwriter advises the Company in writing that marketing factors require a limitation
on the number of shares to be underwritten, the shares held by holders of securities of the Company other than Holders and Other Holders shall be excluded from such Registration Statement and underwriting to the extent deemed advisable by the
managing underwriter, and, if a further reduction of the number of shares is required, the number of shares that may be included in such Registration Statement and underwriting shall be allocated among all Investors first, and all Founders second,
and any remaining shares to the Other Holders requesting registration in proportion, as nearly as practicable, to the respective number of shares of Common Stock (on an as-converted basis) held by them on the date the Company gives the notice
specified in Section 2.2(a). If any Holders or Other Holder would thus be entitled to include more shares than such holder requested to be registered, the excess shall be allocated among other requesting Holders and Other Holders pro rata in
the manner described in the preceding sentence. 

  
 7 

 2.3 Registration Procedures. 

(a) If and whenever the Company is required by the provisions of this Agreement to use its best efforts to effect the registration of any
Registrable Shares under the Securities Act, the Company shall: 
 (i) file with the Commission a Registration Statement with respect to
such Registrable Shares and use its best efforts to cause that Registration Statement to become effective as soon as possible and remain effective for 180 days from the effective date or such lesser period until all such Registrable Shares are sold;

 (ii) as expeditiously as possible prepare and file with the Commission any amendments and supplements to the Registration Statement and
the prospectus included in the Registration Statement as may be necessary to comply with the provisions of the Securities Act (including the anti-fraud provisions thereof) and to keep the Registration Statement effective for 12 months from the
effective date or such lesser period until all such Registrable Shares are sold; 
 (iii) as expeditiously as possible furnish to each
selling Holder such reasonable numbers of copies of the Prospectus, including any preliminary Prospectus, in conformity with the requirements of the Securities Act, and such other documents as such selling Holder may reasonably request in order to
facilitate the public sale or other disposition of the Registrable Shares owned by such selling Holder; 
 (iv) as expeditiously as possible
use its best efforts to register or qualify the Registrable Shares covered by the Registration Statement under the securities or Blue Sky laws of such states as the selling Holders shall reasonably request, and do any and all other acts and things
that may be necessary or desirable to enable the selling Holders to consummate the public sale or other disposition in such states of the Registrable Shares owned by the selling Holders; provided, however, that the Company shall not be
required in connection with this paragraph (iv) to qualify as a foreign corporation or to execute a general consent to service of process in any jurisdiction or to amend its Certificate of Incorporation or By-laws in a manner that the Board of
Directors determines is inadvisable; 
 (v) as expeditiously as possible, cause all such Registrable Shares to be listed on each securities
exchange or automated quotation system on which similar securities issued by the Company are then listed; 
 (vi) promptly provide a
transfer agent and registrar for all such Registrable Shares not later than the effective date of such Registration Statement; 
 (vii)
promptly make available for inspection by the selling Holders, any managing underwriter participating in any disposition pursuant to such Registration Statement, and any attorney or accountant or other agent retained by any such underwriter or
selected by the selling Holders, all financial and other records, pertinent 

  
 8 

 
corporate documents and properties of the Company and cause the Company’s officers, directors, employees and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant or agent in connection with such Registration Statement; 
 (viii) notify each selling
Holder, promptly after it shall receive notice thereof, of the time when such Registration Statement has become effective or a supplement to any Prospectus forming a part of such Registration Statement has been filed; and 

(ix) as expeditiously as possible following the effectiveness of such Registration Statement, notify each seller of such Registrable Shares of
any request by the Commission for the amending or supplementing of such Registration Statement or Prospectus. 
 (b) If the Company has
delivered a Prospectus to the selling Holders and after having done so the Prospectus is amended to comply with the requirements of the Securities Act, the Company shall promptly notify the selling Holders and, if requested, the selling Holders
shall immediately cease making offers of Registrable Shares and return all Prospectuses to the Company. The Company shall promptly provide the selling Holders with revised Prospectuses and, following receipt of the revised Prospectuses, the selling
Holders shall be free to resume making offers of the Registrable Shares. 
 (c) In the event that, in the judgment of the Company, it is
advisable to suspend use of a Prospectus included in a Registration Statement due to pending material developments or other events that have not yet been publicly disclosed and as to which the Company believes public disclosure would be detrimental
to the Company, the Company shall notify all selling Holders to such effect, and, upon receipt of such notice, each such selling Holder shall immediately discontinue any sales of Registrable Shares pursuant to such Registration Statement until such
selling Holder has received copies of a supplemented or amended Prospectus or until such selling Holder is advised in writing by the Company that the then current Prospectus may be used and has received copies of any additional or supplemental
filings that are incorporated or deemed incorporated by reference in such Prospectus. Notwithstanding anything to the contrary herein, the Company shall not exercise its rights under this Section 2.3(c) to suspend sales of Registrable Shares
for a period in excess of 30 days consecutively or 60 days in any 365-day period. 
 2.4 Allocation of Expenses. The Company will pay
all Registration Expenses for all registrations under this Agreement; provided, however, that if a registration under Section 2.1 is withdrawn at the request of the Initiating Holders (other than as a result of information
concerning the business or financial condition of the Company which is made known to the selling Holders after the date on which such registration was requested) and if the Initiating Holders elect not to have such registration counted as a
registration requested under Section 2.1, the selling Holders shall pay the Registration Expenses of such registration pro rata in accordance with the number of their Registrable Shares included in such registration. 

  
 9 

 2.5 Indemnification and Contribution. 

(a) In the event of any registration of any of the Registrable Shares under the Securities Act pursuant to this Agreement, the Company will
indemnify and hold harmless each selling Holder and the partners, members, officers, directors and stockholders of such Holder, each underwriter of such Registrable Shares, and each other person, if any, who controls such selling Holder or
underwriter within the meaning of the Securities Act or the Exchange Act against any losses, claims, damages or liabilities, joint or several, to which such selling Holder, underwriter, controlling person or other aforementioned person or entity may
become subject under the Securities Act, the Exchange Act, state securities or Blue Sky laws or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue
statement or alleged untrue statement of any material fact contained in any Registration Statement under which such Registrable Shares were registered under the Securities Act, any preliminary prospectus or final prospectus contained in the
Registration Statement, or any amendment or supplement to such Registration Statement, (ii) the omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, or
(iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection
with the Registration Statement or the offering contemplated thereby; and the Company will reimburse such selling Holder, underwriter, each such controlling person and or other aforementioned person or entity for any legal or any other expenses
reasonably incurred by such selling Holder, underwriter, controlling person or other aforementioned person or entity in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however,
that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any untrue statement or omission made in such Registration Statement, preliminary prospectus or
prospectus, or any such amendment or supplement, in reliance upon and in conformity with information furnished to the Company, in writing, by or on behalf of such selling Holder, underwriter, controlling person or other aforementioned person or
entity specifically for use in the preparation thereof. 
 (b) In the event of any registration of any of the Registrable Shares under the
Securities Act pursuant to this Agreement, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, each of its directors and officers and each underwriter (if any) and each person, if any, who controls the
Company or any such underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages or liabilities, joint or several, to which the Company, such directors and officers, underwriter or controlling person
may become subject under the Securities Act, Exchange Act, state securities or Blue Sky laws or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue
statement or alleged untrue statement of a material fact contained in any Registration Statement under which such Registrable Shares were registered under the Securities Act, any preliminary prospectus or final prospectus contained in the
Registration Statement, or any amendment or supplement to the Registration Statement, or (ii) any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, if
and to the extent (and only to the extent) that the statement or omission was made in reliance upon and in conformity with information relating to such selling Holder furnished in writing to the Company by such selling Holder specifically for use in
connection 

  
 10 

 
with the preparation of such Registration Statement, prospectus, amendment or supplement; provided, however, that the obligations of a selling Holder hereunder shall be limited to
an amount equal to the net proceeds to such selling Holder of Registrable Shares sold in connection with such registration. 
 (c) Each
Indemnified Party shall give notice to the Indemnifying Party promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such
claim or any litigation resulting therefrom; provided, that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not be unreasonably
withheld, conditioned or delayed); and, provided, further, that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 2.5 except to
the extent that the Indemnifying Party is materially prejudiced by such failure. The Indemnified Party may participate in such defense at such party’s expense; provided, however, that the Indemnifying Party shall pay such expense
if the Indemnified Party reasonably concludes that representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or potential differing interests between the Indemnified Party and any
other party represented by such counsel in such proceeding; provided further that in no event shall the Indemnifying Party be required to pay the expenses of more than one law firm per jurisdiction as counsel for the Indemnified Party.
The Indemnifying Party also shall be responsible for the expenses of such defense if the Indemnifying Party does not elect to assume such defense. No Indemnifying Party, in the defense of any such claim or litigation shall, except with the consent
of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in
respect of such claim or litigation, and no Indemnified Party shall consent to entry of any judgment or settle such claim or litigation without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld,
conditioned or delayed. 
 (d) In order to provide for just and equitable contribution in circumstances in which the indemnification provided
for in this Section 2.5 is due in accordance with its terms but for any reason is held to be unavailable to an Indemnified Party in respect to any losses, claims, damages and liabilities referred to herein, then the Indemnifying Party shall, in
lieu of indemnifying such Indemnified Party, contribute to the amount paid or payable by such Indemnified Party as a result of such losses, claims, damages or liabilities to which such party may be subject in such proportion as is appropriate to
reflect the relative fault of the Company on the one hand and the selling Holders on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative fault of the Company and the selling Holders shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of material fact related to information supplied by the Company or the
selling Holders and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the selling Holders agree that it would not be just and equitable if
contribution pursuant to this Section 2.5(d) were determined by pro rata allocation or by any other method of allocation 

  
 11 

 
which does not take account of the equitable considerations referred to above. Notwithstanding the provisions of this Section 2.5(d), (i) in no case shall any one selling Holder be
liable or responsible for any amount in excess of the net proceeds received by such selling Holder from the offering of Registrable Shares and (ii) the Company shall be liable and responsible for any amount in excess of such proceeds;
provided, however, that no person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. Any party entitled to contribution will, promptly after receipt of notice of commencement of any action, suit or proceeding against such party in respect of which a claim for contribution may be made against another party or
parties under this Section 2.5(d), notify such party or parties from whom contribution may be sought, but the omission so to notify such party or parties from whom contribution may be sought shall not relieve such party from any other
obligation it or they may have thereunder or otherwise under this Section 2.5(d). No party shall be liable for contribution with respect to any action, suit, proceeding or claim settled without its prior written consent, which consent shall not
be unreasonably withheld, conditioned or delayed. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification
and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) The rights and obligations of the Company and the selling Holders under this Section 2.5 shall survive the termination of this
Agreement. 
 2.6 Other Matters with Respect to Underwritten Offerings. In the event that Registrable Shares are sold pursuant to a
Registration Statement in an underwritten offering pursuant to Section 2.1, the Company agrees to (a) enter into an underwriting agreement containing customary representations and warranties with respect to the business and operations of
the Company and customary covenants and agreements to be performed by the Company, including without limitation customary provisions with respect to indemnification by the Company of the underwriters of such offering; (b) use its best efforts
to cause its legal counsel to render customary opinions to the underwriters with respect to the Registration Statement; and (c) use its best efforts to cause its independent public accounting firm to issue customary “cold comfort
letters” to the underwriters with respect to the Registration Statement. 
 2.7 Information by Holder. Each holder of Registrable
Shares included in any registration shall furnish to the Company such information regarding such holder and the distribution proposed by such holder as the Company may reasonably request in writing and as shall be required in connection with any
registration, qualification or compliance referred to in this Agreement. 
 2.8 “Lock-Up” Agreement; Confidentiality of
Notices. Each Holder, if requested by the Company and the managing underwriter of the Initial Public Offering, shall not sell or otherwise transfer or dispose of any Registrable Shares or other securities of the Company (excluding securities
acquired in the Initial Public Offering or in the public market after such offering) held by such Holder for a period of 180 days following the effective date of the Registration Statement for the Initial Public Offering; provided, that all
stockholders of the 

  
 12 

 
Company then holding at least 2% of the outstanding Common Stock (on an as-converted basis) and all officers and directors of the Company enter into similar agreements, and any discretionary
modification, waiver or termination of the restrictions of such agreements (including this agreement) by the Company or the managing underwriter shall apply to all persons subject to such agreements on a pro rata basis, based upon the number of
shares held by each subject to such agreements. 
 The Company may impose stop-transfer instructions with respect to the Registrable Shares
or other securities subject to the foregoing restriction until the end of such 180-day period, which period may be extended upon the request of the managing underwriter, to the extent required by any FINRA rules, for an additional period of up to
fifteen (15) days if the Company issues or proposes to issue an earnings or other public release within (15) days of the expiration of the 180-day lockup period. 

Any Holder receiving any written notice from the Company regarding the Company’s plans to file a Registration Statement shall treat such
notice confidentially and shall not disclose such information to any person other than as necessary to exercise its rights under this Agreement. 

Notwithstanding the foregoing, any person or entity to which any Shares or Registrable Shares are transferred by a Holder, whether voluntarily
or by operation of law, shall be bound by the obligations under Section 2.8 to the same extent as if such transferee were a Holder hereunder and no Holder shall transfer any Shares or Registrable Shares unless the transferee provides a written
instrument to the Company notifying the Company of such transfer and agreeing in writing to be bound by the terms of Section 2.8. 
 2.9
Rule 144 Requirements. After the earliest of (i) the closing of the sale of securities of the Company pursuant to a Registration Statement, (ii) the registration by the Company of a class of securities under Section 12 of the
Exchange Act, or (iii) the issuance by the Company of an offering circular pursuant to Regulation A under the Securities Act, the Company agrees to: 

(a) make and keep current public information about the Company available, as those terms are understood and defined in Rule 144; 

(b) use its best efforts to file with the Commission in a timely manner all reports and other documents required of the Company under the
Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements); and 
 (c) furnish to any
holder of Registrable Shares upon request (i) a written statement by the Company as to its compliance with the reporting requirements of Rule 144 and of the Securities Act and the Exchange Act (at any time after it has become subject to such
reporting requirements), (ii) a copy of the most recent annual or quarterly report of the Company, and (iii) such other reports and documents of the Company as such holder may reasonably request to avail itself of any similar rule or
regulation of the Commission allowing it to sell any such securities without registration. 

  
 13 

 2.10 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Shares then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would
allow such holder or prospective holder (i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that
the inclusion of such securities will not reduce the number of the Registrable Shares of the Holders that are included or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder
or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement pursuant to Section 6.1. 

2.11 Termination. All of the Company’s obligations to register Registrable Shares under Sections 2.1 and 2.2 shall terminate upon
the earliest of (a) five (5) years after the closing of the Initial Public Offering, (b) the date on which no Holder holds any Registrable Shares or (c) the closing of a Deemed Liquidation Event, as such term is defined in the
Company’s Certificate of Incorporation. 
 3. Right of First Refusal. 

3.1 Rights of Investors to Acquire Offered Securities. 

(a) So long as at least 15% (subject to appropriate adjustment for stock splits, stock dividends, recapitalizations and similar events
occurring after the date of this Agreement) of the shares of Preferred Stock (or the Common Stock issuable or issued upon conversion of the Preferred Stock) outstanding as of the date hereof remains outstanding, the Company shall not issue, sell or
exchange, agree to issue, sell or exchange, or reserve or set aside for issuance, sale or exchange, any Offered Securities, unless in each such case the Company shall have first complied with this Section 3.1. The Company shall deliver to each
Investor an Offer, which shall (i) identify and describe the Offered Securities, (ii) describe the price and other terms upon which they are to be issued, sold or exchanged, and the number or amount of the Offered Securities to be issued,
sold or exchanged, (iii) identify the persons or entities (if known) to which or with which the Offered Securities are to be offered, issued, sold or exchanged, and (iv) offer to issue and sell to or exchange with such Investor that is a
Qualified Investor (A) such Qualified Investor’s Basic Amount and (B) such Qualified Investor’s Undersubscription Amount based on the Available Undersubscription Amount. 

(b) To accept an Offer, in whole or in part, a Qualified Investor must deliver to the Company, on or prior to the date 30 days after the date
of delivery of the Offer, a Notice of Acceptance providing a representation letter certifying that such Qualified Investor is an accredited investor within the meaning of Rule 501 under the Securities Act and indicating the portion of the Qualified
Investor’s Basic Amount that such Qualified Investor elects to purchase and, if such Qualified Investor shall elect to purchase all of its Basic Amount, the Undersubscription Amount (if any) that such Qualified Investor elects to purchase. If
the Basic Amounts subscribed for by all Qualified Investors are less than the total of all of the Basic Amounts available for purchase, then each Qualified Investor who has set forth an Undersubscription Amount in its Notice of Acceptance shall be
entitled to purchase, in addition 

  
 14 

 
to the Basic Amounts subscribed for, the Undersubscription Amount it has subscribed for; provided, however, that if the Undersubscription Amounts subscribed for exceed the Available
Undersubscription Amount, each Qualified Investor who has subscribed for any Undersubscription Amount shall be entitled to purchase only that portion of the Available Undersubscription Amount as the Undersubscription Amount subscribed for by such
Qualified Investor bears to the total Undersubscription Amounts subscribed for by all Investors, subject to rounding by the Board of Directors to the extent it deems reasonably necessary. 

(c) In the event that Notices of Acceptance are not given by such Investors in respect of all Offered Securities, the Company shall have 90
days after the date of delivery of the Offer set forth in Section 3.1(a) to issue, sell or exchange all or any part of the Offered Securities (subject to reserving any Offered Securities required to satisfy any outstanding Offers to Investors),
but only to the offerees or Investors described in the Offer (if so described therein) and only upon terms and conditions (including, without limitation, unit prices and interest rates) which are not more favorable, in the aggregate, to the
acquiring person or persons or less favorable to the Company than those set forth in the Offer. 
 (d) In the event the Company shall
propose to sell less than all the Refused Securities, then each Qualified Investor may, at its sole option and in its sole discretion, reduce the number or amount of the Offered Securities specified in its Notice of Acceptance to an amount that
shall be not less than the number or amount of the Offered Securities that the Qualified Investor elected to purchase pursuant to Section 3.1(b) multiplied by a fraction, (i) the numerator of which shall be the number or amount of Offered
Securities the Company actually proposes to issue, sell or exchange (including Offered Securities to be issued or sold to Qualified Investors pursuant to Section 3.1(b) prior to such reduction) and (ii) the denominator of which shall be
the original amount of the Offered Securities. In the event that any Qualified Investor so elects to reduce the number or amount of Offered Securities specified in its Notice of Acceptance, the Company may not issue, sell or exchange more than the
reduced number or amount of the Offered Securities unless and until such securities have again been offered to the Qualified Investors in accordance with Section 3.1(a). 

(e) Upon the closing of the issuance, sale or exchange of all or less than all of the Refused Securities, such Qualified Investor or Investors
shall acquire from the Company and the Company shall issue to such Qualified Investor or Investors, the number or amount of Offered Securities specified in the Notices of Acceptance, as reduced pursuant to Section 3.1(d) if any of the Qualified
Investors has so elected, upon the terms and conditions specified in the Offer. 
 (f) The purchase by the Qualified Investors of any
Offered Securities is subject in all cases to the preparation, execution and delivery by the Company and the Qualified Investors of a purchase agreement relating to such Offered Securities reasonably satisfactory in form and substance to the
Qualified Investors and their respective counsel. 
 (g) Any Offered Securities not acquired by the Qualified Investors or other persons in
accordance with Section 3.1(c) may not be issued, sold or exchanged until they are again offered to the Qualified Investors under the procedures specified in this Agreement. 

  
 15 

 (h) The rights of the Qualified Investors under this Section 3.1 shall not apply to: 

(i) the issuance of any shares of Common Stock as a stock dividend to holders of Common Stock or upon any subdivision or combination of shares
of Common Stock; 
 (ii) the issuance of any shares of Common Stock upon conversion of shares of convertible preferred stock; 

(iii) the issuance of shares of Common Stock or options with respect thereto (subject in either case to appropriate adjustment for stock
splits, stock dividends, recapitalizations and similar events occurring after the date of this Agreement), issued or issuable to employees, directors or officers of, or consultants to, the Company or any Company Subsidiary pursuant to any plan,
agreement or arrangement approved by the Board of Directors including the directors elected by the holders of the Preferred Stock (the “Preferred Directors”), if any; 

(iv) the issuance of securities solely in consideration for the acquisition (whether by merger or otherwise) by the Company or any Company
Subsidiary of all or substantially all of the stock or assets of any other entity approved by the Board of Directors including the Preferred Directors; 

(v) the issuance of shares of Common Stock by the Company in the Initial Public Offering; or 

(vi) the issuance of shares of Common Stock, or the grant of options or warrants therefor, in connection with any present or future borrowing,
line of credit, leasing or similar financing arrangement approved by the Board of Directors, including the Preferred Directors, if any. 

3.2 Termination. This Section 3 shall terminate upon the earlier of the closing of a Deemed Liquidation Event or the closing of an
Initial Public Offering. 
 4. Covenants. 

4.1 Affirmative and Negative Covenants. So long as at least 20% (subject to appropriate adjustment for stock splits, stock dividends,
recapitalizations and similar events occurring after the date of this Agreement) of the shares of Preferred Stock (or the Common Stock issuable or issued upon conversion of the Preferred Stock) outstanding as of the date hereof are outstanding, the
Company covenants and agrees that it will perform and observe the following covenants and provisions and will cause each Company Subsidiary to perform and observe such of the following covenants and provisions as are applicable to such Company
Subsidiary: 
 (a) Maintenance of Insurance. Maintain with responsible and reputable insurance companies or associations, directors
and officers insurance, in such amounts and covering such risks as may be approved by the Preferred Directors, if any. 

  
 16 

 (b) Key Person Life Insurance. The Company shall obtain as promptly as practicable
following the date of this Agreement and shall thereafter maintain “key person” life insurance on Amarpreet Sawhney in an amount equal to $1,000,000 which names the Company as loss payee, from financially sound and reputable insurers at
the time the policy is purchased until such time as the Board of Directors, including the Preferred Directors, determines that such insurance should be discontinued. 

(c) Confidentiality and Proprietary Information Agreements. The Company will cause (i) each person now or hereafter employed by it
or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets or who develops or creates intellectual property for the Company or any subsidiary
to enter into a nondisclosure and proprietary rights assignment agreement and (ii) each person now or hereafter employed by it or by any subsidiary to enter into a one (1) year noncompetition and nonsolicitation agreement, substantially in
the form presently used by the Company unless otherwise approved by the Board of Directors, including the Preferred Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the
above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of the Preferred Directors. 

(d) Stock Options. Unless otherwise authorized by the Board of Directors (including the Preferred Directors), all stock options or
shares of restricted stock granted after the date hereof to employees of the Company shall be subject to vesting over a period of four (4) years, with 25% vesting on the first anniversary of the grant date and the remaining vesting monthly
thereafter in equal amounts until fully vested on the fourth anniversary of the grant date, and shall contain a market “stand-off” provision substantially similar to Section 2.8. In addition, unless otherwise approved by the Board of
Directors, the Company shall retain a “right of first refusal” on employee transfers until the Company’s Initial Public Offering and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder
of restricted stock. 
 (e) Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the
Board of Directors shall meet at least monthly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors and the CHV Observer (as defined below) and Baxter Observer (as defined below) for all reasonable
out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. The Company shall cause to be established and will maintain a compensation committee, which
shall consist of two Preferred Directors and an outside independent director. The compensation committee shall recommend compensation for the president and chief executive officer of the Company and other senior management of the Company, including
option grants and other equity compensation and shall consider such other matters as may be delegated to it by the Board of Directors. 

  
 17 

 (f) Qualified Small Business Stock. The Company shall use commercially reasonable efforts
to cause the shares of Preferred Stock, as well as any shares into which such shares are converted, within the meaning of Section 1202(f) of the Internal Revenue Code of 1986, as amended (the “Code”), to constitute “qualified
small business stock” as defined in Section 1202(c) of the Code; provided, however, that such requirement shall not be applicable if the Board of Directors determines, in its good-faith business judgment, that such
qualification is inconsistent with the best interests of the Company. The Company shall submit to its stockholders (including the Investors) and to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the
Code and the regulations promulgated thereunder. In addition, within twenty (20) business days after any Investor’s written request therefor, the Company shall, at its option, either (i) deliver to such Investor a written statement
indicating whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code or (ii) deliver to such Investor such factual
information in the Company’s possession as is reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor’s interest in the Company constitutes “qualified small business stock” as defined
in Section 1202(c) of the Code. 
 4.2 Inspection. So long as at least 20% (subject to appropriate adjustment for stock splits,
stock dividends, recapitalizations and similar events occurring after the date of this Agreement) of the shares of Preferred Stock (or the Common Stock issuable or issued upon conversion of the Preferred Stock) are outstanding as of the date hereof,
the Company shall permit each Major Investor, or any authorized representative thereof, to visit and inspect the properties of the Company, including its corporate and financial records, and to discuss its business and finances with officers of the
Company, during normal business hours following reasonable notice and as often as may be reasonably requested; provided, however, that the Company shall not be obligated pursuant to this Section 4.2 to provide access to any
information which it reasonably considers to be a trade secret. 
 4.3 Financial Statements and Other Information. 

(a) So long as at least 20% (subject to appropriate adjustment for stock splits, stock dividends, recapitalizations and similar events
occurring after the date of this Agreement) of the shares of Preferred Stock (or the Common Stock issuable or issued upon conversion of the Preferred Stock) are outstanding as of the date hereof, the Company shall deliver to each Major Investor:

 (i) within 90 days after the end of each fiscal year of the Company, an audited balance sheet of the Company as at the end of such
year and audited statements of income and of cash flows of the Company for such year, certified by certified public accountants of established national reputation selected by the Company, and prepared in accordance with generally accepted accounting
principles consistently applied; 
 (ii) within 45 days after the end of each fiscal quarter of the Company (other than the fourth quarter),
an unaudited balance sheet of the Company as at the end of such quarter, and unaudited statements of income and of cash flows of the Company for such fiscal quarter and for the current fiscal year to the end of such fiscal quarter; 

(iii) within 15 days after the end of each calendar month, an unaudited balance sheet of the Company as at the end of such month, and
unaudited statement of income and of cash flows of the Company for such calendar month and for the current fiscal year to the end of such fiscal month; and 

  
 18 

 (iv) as soon as available, but in any event prior to the commencement of each new fiscal year, a
business plan and projected financial statements for such fiscal year. 
 4.4 Observer Rights. (i) As long as CHV II, LP
(“CHV”) or its Affiliated Parties owns shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall invite a representative of CHV (the “CHV Observer”) to attend all meetings of the Board of
Directors in a nonvoting observer capacity and (ii) as long as Baxter Healthcare Corporation (“Baxter”) or its Affiliated Parties owns shares of Preferred Stock (or Common Stock issued upon conversion thereof), the Company shall
invite a representative of Baxter (the “Baxter Observer”) to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give the CHV Observer and Baxter Observer copies of all notices,
minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that each of the CHV Observer and Baxter Observer shall agree to hold in
confidence all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude the CHV Observer or Baxter Observer from any meeting or portion thereof if access to such information or
attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or the CHV Observer or Baxter Observer is a
competitor of the Company. 
 4.5 Termination of Covenants. All covenants of the Company contained in this Section 4 shall
terminate upon the earlier of the closing of a Deemed Liquidation Event or the closing of an Initial Public Offering. 
 5.
Confidentiality. Each Investor agrees that he, she or it will keep confidential and will not disclose, divulge or use for any purpose, other than to monitor its investment in the Company, any Confidential Information; provided,
however, that an Investor may disclose Confidential Information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the
Company, (ii) to any prospective purchaser of any Shares from such Investor as long as such prospective purchaser agrees to be bound by terms of a confidentiality agreement reasonably approved by the Company, (iii) to any Affiliated Party
of such Investor, provided that such party is obligated not to disclose, divulge or use any Confidential Information to the same extent as the Investors, or (iv) as may otherwise be required by law, provided that the Investor takes reasonable
steps to minimize the extent of any such required disclosure. Notwithstanding the foregoing, such information shall not be deemed confidential for the purpose of enforcing this Agreement. 

6. Transfers of Rights; Calculation of Share Numbers. 

  
 19 

 6.1 Transfer of Rights. This Agreement, and the rights and obligations of each Investor
hereunder, may be assigned by such Investor to (a) any person or entity to which at least 5% (subject to appropriate adjustment for stock splits, stock dividends, recapitalizations and similar events occurring after the date of this Agreement)
of the shares of Preferred Stock (or the Common Stock issuable or issued upon conversion of the Preferred Stock) owned by such Investor as of the date hereof are transferred by such Investor, or (b) to any Affiliated Party, shareholder or
partner of such Investor, and, in each case, such transferee shall be deemed a “Investor” for purposes of this Agreement; provided that such assignment of rights shall be contingent upon the transferee providing a written instrument to the
Company notifying the Company of such transfer and assignment and delivering to the Company a counterpart signature page hereto pursuant to which such transferee shall confirm their agreement to be subject to and bound by all of the provisions set
forth in this Agreement, including Section 2.8. Notwithstanding the foregoing, no Investor shall transfer any Shares to (a) any entity which, in the reasonable determination of the Board of Directors, directly or indirectly competes with
the Company or (b) any customer, distributor or supplier of the Company, if the Board of Directors should reasonably determine that such transfer would result in such customer, distributor or supplier receiving information that would place the
Company at a competitive disadvantage with respect to such customer, distributor or supplier. 
 6.2 Calculation of Share Numbers. In
determining the number of Shares owned by an Investor for purposes of exercising rights under this Agreement, (a) Shares owned by an Investor shall be deemed to include shares of Preferred Stock which have been converted into Common Stock so
long as such Common Stock is owned by such Investor and (b) all Shares held by an Affiliated Party of such Investor shall be aggregated together (provided that no shares shall be attributed to more than one entity or person within any such
group of Affiliated Parties). 
 7. General. 

7.1 Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability
of any other provision of this Agreement. 
 7.2 Specific Performance. In addition to any and all other remedies that may be available
at law in the event of any breach of this Agreement, each Investor shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunctive or other equitable relief as may be granted by a
court of competent jurisdiction. 
 7.3 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws
of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of law. 
 7.4
Notices. All notices, requests, consents and other communications under this Agreement shall be in writing and shall be deemed delivered (i) three business days after being sent by registered or certified mail, return receipt requested,
postage prepaid or (ii) one business day after being sent via a reputable nationwide overnight courier service guaranteeing next business day delivery, in each case to the intended recipient as set forth below: 

  
 20 

 If to the Company, at 204 2nd Avenue, Waltham, MA 02451, Attention: President, or at such other
address as may have been furnished in writing by the Company to the other parties hereto, with a copy (which shall not constitute notice) to Steven Cagnetta, Company Counsel, LLC, 28 Stone Avenue, Winchester, MA 01890; or 

If to a Investor, at its address set forth on Exhibit A, or at such other address as may have been furnished in writing by such
Investor to the other parties hereto; and if notice is given to such Investors, a copy (which shall not constitute notice) shall also be given to Michael P. Earley, Jones Day, 77 W. Wacker Dr., Chicago, IL 60601, Fax No: (312) 782-8585 and
Michael H. Bison, Esq., Goodwin Procter LLP, 53 State Street, Boston, MA 02109, Fax: (617) 523-1231. 
 Any party may give any notice,
request, consent or other communication under this Agreement using any other means (including, without limitation, personal delivery, messenger service, telecopy, first class mail or electronic mail), but no such notice, request, consent or other
communication shall be deemed to have been duly given unless and until it is actually received by the party for whom it is intended. Any party may change the address to which notices, requests, consents or other communications hereunder are to be
delivered by giving the other parties notice in the manner set forth in this Section 7.4. 
 7.5 Termination of Prior Agreement;
Complete Agreement. The parties hereto who are also parties to the Prior Agreement, agree that this Agreement amends and restates in its entirety the Prior Agreement and the Prior Agreement shall have no further force or effect. This Agreement
constitutes the entire agreement and understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings relating to such subject matter. 

7.6 Amendments and Waivers. This Agreement may be amended or terminated and the observance of any term of this Agreement may be waived
with respect to all parties to this Agreement (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and Investors holding Shares representing at least a majority of the
voting power of all Shares then held by Investors; provided that any amendment, termination or waiver to the terms of Section 2 (or a defined term used therein) that occurs after the closing of the Initial Public Offering shall instead require
the written consent of the Company and Investors holding Registrable Shares representing at least a majority of the voting power of all Registrable Shares then held by all Investors. Notwithstanding the foregoing, (a) this Agreement may not be
amended or terminated and the observance of any term hereunder may not be waived with respect to any Investor without the written consent of such Investor unless such amendment, termination or waiver applies to all Investors in the same fashion (it
being agreed that a waiver of the provisions of Section 3 with respect to a particular transaction shall be deemed to apply to all Qualified Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that
certain Qualified Investors may nonetheless, by agreement with the Company, purchase securities in such transaction) and (b) neither the rights of Baxter or CHV pursuant to Section 4.4 of this Agreement, the terms of such section nor this
clause (b) may be amended, terminated or waived without the written consent of Baxter or CHV, as applicable. The Company shall give prompt written notice of any amendment or termination hereof or waiver

  
 21 

 
hereunder to any party hereto that did not consent in writing to such amendment, termination or waiver. Any amendment, termination or waiver effected in accordance with this Section 7.6
shall be binding on all parties hereto, even if they do not execute such consent. No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or construed as, a further or
continuing waiver of any such term, condition or provision. 
 7.7 Pronouns. Whenever the context may require, any pronouns used in
this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. 

7.8 Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which shall be deemed to
be an original, and all of which together shall constitute one and the same document. Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have
been duly and validly delivered and be valid and effective for all purposes. 
 7.9 Section Headings and References. The section
headings are for the convenience of the parties and in no way alter, modify, amend, limit or restrict the contractual obligations of the parties. Any reference in this agreement to a particular section or subsection shall refer to a section or
subsection of this Agreement, unless specified otherwise. 
 [Remainder of Page Intentionally Left Blank] 

  
 22 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amended and Restated Investor Rights
Agreement as of the date first written above. 
 COMPANY: 

OCULAR THERAPEUTIX, INC. 
  

			
	By:	 	 /s/ Amarpreet Sawhney

	Name:	 	Amarpreet Sawhney
	Title:	 	President

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

 OCULAR THERAPEUTIX, INC. 

Fourth Amended and Restated Investor Rights Agreement 

Investor Signature Page 

By executing this page in the space provided, the undersigned hereby agrees (i) that he, she or it is an “Investor” as defined
in the Fourth Amended and Restated Investor Rights Agreement dated as of May 31, 2013 (as the same may be amended, modified or restated from time to time, the “Investor Rights Agreement”), by and among Ocular Therapeutix, Inc. and the
parties named therein, (ii) that he, she or it is a party to the Investor Rights Agreement for all purposes and (iii) that he, she or it is bound by all terms and conditions of the Investor Rights Agreement. 

EXECUTED this 31st day of May, 2013. 
  

			
	 BAXTER HEALTHCARE

CORPORATION

		
	By: 	 	 /s/ Robert J. Hombach

	Title: 	 	CVP, Chief Financial Officer
		
	Address:	 	One Baxter Parkway
		
		 	Deerfield, IL 60015
		
	Phone:	 	(224) 948-4310
		
	Facsimile:	 	(224) 948-2590
		
	Email:	 	bob_hombach@baxter.com

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

 OCULAR THERAPEUTIX, INC. 

Fourth Amended and Restated Investor Rights Agreement 

Investor Signature Page 

By executing this page in the space provided, the undersigned hereby agrees (i) that he, she or it is an “Investor” as defined
in the Fourth Amended and Restated Investor Rights Agreement dated as of May 31, 2013 (as the same may be amended, modified or restated from time to time, the “Investor Rights Agreement”), by and among Ocular Therapeutix, Inc. and the
parties named therein, (ii) that he, she or it is a party to the Investor Rights Agreement for all purposes and (iii) that he, she or it is bound by all terms and conditions of the Investor Rights Agreement. 

EXECUTED this 31st day of May, 2013. 
  

			
	CHV II, LP
		
	By: 	 	 /s/ Matthew I. Hermann

	Title: 	 	Senior Managing Director
		
	Address:	 	101 South Hanley Road,
		
		 	Suite 200
		
		 	Clayton, MO 63015
	
	Amount invested: $2,000,001

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

 OCULAR THERAPEUTIX, INC. 

Fourth Amended and Restated Investor Rights Agreement 

Investor Signature Page 

By executing this page in the space provided, the undersigned hereby agrees (i) that he, she or it is an “Investor” as defined
in the Fourth Amended and Restated Investor Rights Agreement dated as of May 31, 2013 (as the same may be amended, modified or restated from time to time, the “Investor Rights Agreement”), by and among Ocular Therapeutix, Inc. and the
parties named therein, (ii) that he, she or it is a party to the Investor Rights Agreement for all purposes and (iii) that he, she or it is bound by all terms and conditions of the Investor Rights Agreement. 

EXECUTED this 31st day of May, 2013. 
  

			
	JAMES FORTUNE
		
	By: 	 	 /s/ James Fortune

	Title: 	 	Chief Operating Officer
		
	Address:	 	35 Shepherd Street
		
		 	Foxboro, MA 02035
		
	Email:	 	jfortune@ocutx.com
		
	Fax:	 	(781) 357-4001

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

 OCULAR THERAPEUTIX, INC. 

Fourth Amended and Restated Investor Rights Agreement 

Investor Signature Page 

By executing this page in the space provided, the undersigned hereby agrees (i) that he, she or it is an “Investor” as defined
in the Fourth Amended and Restated Investor Rights Agreement dated as of May 31, 2013 (as the same may be amended, modified or restated from time to time, the “Investor Rights Agreement”), by and among Ocular Therapeutix, Inc. and the
parties named therein, (ii) that he, she or it is a party to the Investor Rights Agreement for all purposes and (iii) that he, she or it is bound by all terms and conditions of the Investor Rights Agreement. 

EXECUTED this 31st day of May, 2013. 
  

			
	SPARTA GROUP MA LLC SERIES 12
		
	By: 	 	 /s/ Nirav Desai

	Title:	 	Managing Director
		
	Address:	 	92 Montvale Avenue
		
		 	Suite 2500
		
		 	Stoneham, MA 02180
		
	Email:	 	serge@spartagroupllc.com
		
	Fax:	 	(781) 481-9155

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

 OCULAR THERAPEUTIX, INC. 

Fourth Amended and Restated Investor Rights Agreement 

Investor Signature Page 

By executing this page in the space provided, the undersigned hereby agrees (i) that he, she or it is an “Investor” as defined
in the Fourth Amended and Restated Investor Rights Agreement dated as of May 31, 2013 (as the same may be amended, modified or restated from time to time, the “Investor Rights Agreement”), by and among Ocular Therapeutix, Inc. and the
parties named therein, (ii) that he, she or it is a party to the Investor Rights Agreement for all purposes and (iii) that he, she or it is bound by all terms and conditions of the Investor Rights Agreement. 

EXECUTED this 31st day of May, 2013. 
  

			
	SV LIFE SCIENCES FUND IV, L.P.
	
	 By: SV Life Sciences Fund IV (GP), L.P.

its sole General Partner

	
	 By: SVLSF IV, LLC
 its sole General
Partner

		
	By: 	 	 /s/ Denise W. Marks

	Title:	 	SVLSF IV, LLC, Member
		
	Address:	 	One Boston Place
		
		 	Suite 3900
		
		 	Boston, MA 02108
		
	Email:	 	denise.marks@svlsa.com
		
	Fax:	 	(617) 367-1590

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

 OCULAR THERAPEUTIX, INC. 

Fourth Amended and Restated Investor Rights Agreement 

Investor Signature Page 

By executing this page in the space provided, the undersigned hereby agrees (i) that he, she or it is an “Investor” as defined
in the Fourth Amended and Restated Investor Rights Agreement dated as of May 31, 2013 (as the same may be amended, modified or restated from time to time, the “Investor Rights Agreement”), by and among Ocular Therapeutix, Inc. and the
parties named therein, (ii) that he, she or it is a party to the Investor Rights Agreement for all purposes and (iii) that he, she or it is bound by all terms and conditions of the Investor Rights Agreement. 

EXECUTED this 31st day of May, 2013. 
  

			
	 SV LIFE SCIENCES FUND IV

STRATEGIC PARTNERS, L.P.

	
	 By: SV Life Sciences Fund IV (GP), L.P.

its sole General Partner

	
	 By: SVLSF IV, LLC
 its sole General
Partner

		
	By: 	 	 /s/ Denise W. Marks

	Title:	 	SVLSF IV, LLC, Member
		
	Address:	 	One Boston Place
		
		 	Suite 3900
		
		 	Boston, MA 02108
		
	Email:	 	denise.marks@svlsa.com
		
	Fax:	 	(617) 367-1590

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

 OCULAR THERAPEUTIX, INC. 

Fourth Amended and Restated Investor Rights Agreement 

Investor Signature Page 

By executing this page in the space provided, the undersigned hereby agrees (i) that he, she or it is an “Investor” as defined
in the Fourth Amended and Restated Investor Rights Agreement dated as of May 31, 2013 (as the same may be amended, modified or restated from time to time, the “Investor Rights Agreement”), by and among Ocular Therapeutix, Inc. and the
parties named therein, (ii) that he, she or it is a party to the Investor Rights Agreement for all purposes and (iii) that he, she or it is bound by all terms and conditions of the Investor Rights Agreement. 

EXECUTED this 31st day of May, 2013. 
  

			
	VERSANT VENTURE CAPITAL III, L.P.
	VERSANT SIDE FUND III, L.P
		
	By: 	 	 /s/ Charles Warden

	Title: 	 	Managing Director
		
	Address:	 	3000 Sand Hill Road
		
		 	Building 4, Suite 210
		
		 	Menlo Park, CA 94025
		
	Email:	 	cwarden@versantventures.com
		
	Fax:	 	(650) 854-9513

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

 OCULAR THERAPEUTIX, INC. 

Fourth Amended and Restated Investor Rights Agreement 

Founder Signature Page 

By executing this page in the space provided, the undersigned hereby agrees (i) that he, she or it is an “Founder” as defined
in the Fourth Amended and Restated Investor Rights Agreement dated as of May 31, 2013 (as the same may be amended, modified or restated from time to time, the “Investor Rights Agreement”), by and among Ocular Therapeutix, Inc. and the
parties named therein, (ii) that he, she or it is a party to the Investor Rights Agreement for all purposes and (iii) that he, she or it is bound by all terms and conditions of the Investor Rights Agreement. 

EXECUTED this 31st day of May, 2013. 
  

			
	AMARPREET S. SAWHNEY
		
	By: 	 	 /s/ Amarpreet S. Sawhney

		
	Address:	 	6 Porter Lane
		
		 	Lexington, MA 02420
	
	  

		
	Email:	 	  

		
	Fax:	 	  

 SIGNATURE PAGE TO FOURTH AMENDED AND RESTATED 

INVESTOR RIGHTS AGREEMENT 

 OCULAR THERAPEUTIX, INC. 

Fourth Amended and Restated Investor Rights Agreement 

Founder Signature Page 

By executing this page in the space provided, the undersigned hereby agrees (i) that he, she or it is an “Founder” as defined
in the Fourth Amended and Restated Investor Rights Agreement dated as of May 31, 2013 (as the same may be amended, modified or restated from time to time, the “Investor Rights Agreement”), by and among Ocular Therapeutix, Inc. and the
parties named therein, (ii) that he, she or it is a party to the Investor Rights Agreement for all purposes and (iii) that he, she or it is bound by all terms and conditions of the Investor Rights Agreement. 

EXECUTED this 31st day of May, 2013. 
  

			
	FARHARD KHOSRAVI
		
	By: 	 	 /s/ Farhad Khosravi

		
	Address:	 	25698 Elena Road
		
		 	Los Altos Hills, CA 94022
	
	  

		
	Email:	 	fkhosravi@me.com
		
	Fax:	 	  

 OCULAR THERAPEUTIX, INC. 

Fourth Amended and Restated Investor Rights Agreement 

Founder Signature Page 

By executing this page in the space provided, the undersigned hereby agrees (i) that he, she or it is an “Founder” as defined
in the Fourth Amended and Restated Investor Rights Agreement dated as of May 31, 2013 (as the same may be amended, modified or restated from time to time, the “Investor Rights Agreement”), by and among Ocular Therapeutix, Inc. and the
parties named therein, (ii) that he, she or it is a party to the Investor Rights Agreement for all purposes and (iii) that he, she or it is bound by all terms and conditions of the Investor Rights Agreement. 

EXECUTED this 31st day of May, 2013. 
  

			
	INCEPT, LLC
		
	By: 	 	 /s/ Farhad Khosravi

	Title: 	 	Manager
		
	Address:	 	25698 Elena Road
		
		 	Los Altos Hills, CA 94022
	
	
	Email:	 	fkhosravi@me.com
		
	Fax:	 	  

 Exhibit A 

Investors 
  

			
	Incept, LLC	  	 c/o Farhad Khosravi, 1198 Longfellow Ave.,

Campbell, CA 95008

		
	Glevel, LLC	  	 3200 Alpine Road, Portola Valley, California

94028, Attn Stephen Bonelli

		
	Versant Venture Capital III, L.P.	  	 3000 Sand Hill Road, Bldg 4, Suite 210,
 Menlo
Park, CA 94025, Attn: Charles
 Warden

		
	Versant Side Fund III, L.P.	  	 3000 Sand Hill Road, Bldg 4, Suite 210,
 Menlo
Park, CA 94025, Attn: Charles
 Warden

		
	Ann A. Hopkins	  	49 Cleveland Avenue, Buffalo, NY 14222
		
	Richard L. Lindstrom, M.D.	  	 710 E. 24th Street Suite 106
 Minneapolis, MN
55404

		
	Running Brook LP	  	 C/o Mark Hughes, 73 Chatham Street,
 Brookline,
MA 02446

		
	Navdeep Chadha	  	6 Reed Dr. North, Princeton Jct., NJ 08550
		
	Jaswinder Chadha	  	31 Strawberry Lane, Warren, NJ 07059
		
	 Farhad Khosravi & Flora Shirzad Khosravi

Trust u/a/d 10/19/2004
	  	 25698 Elena Road, Los Altos Hills, CA

94022

		
	The Mehta Family Trust for Anjali Mehta	  	 c/o Anjali Bhagwati-Mehta, 5 Granger Pond
 Way,
Lexington, MA 02420

		
	Quechee Partners, LLC	  	 Francis J. Feeney, Jr., DLA Piper, 33 Arch

Street, Boston, MA 02110

		
	Ravijit Paintal	  	15 Idylwilde Road, Lexington, MA 02421-7601
		
	Stephen Ramee	  	348 Bellaire Dr., New Orleans, LA 70124
		
	Shingleton Family Limited Partnership	  	 c/o Bradford J. Shingleton, 43 Chestnut
 Street,
Boston, MA 02108

		
	SV Life Sciences Fund IV, L.P.	  	 SV Life Sciences, 60 State Street, Suite 3650,

Boston, MA. 02109

		
	SV Life Sciences Fund IV Strategic Partners L.P.	  	 SV Life Sciences, 60 State Street, Suite 3650,

Boston, MA. 02109

		
	PINNACLE VENTURES II-A, L.P.	  	 Pinnacle Ventures, L.L.C., 130 Lytton
 Avenue,
Suite 220, Palo Alto, CA 94301

		
	PINNACLE VENTURES II-B, L.P.	  	 Pinnacle Ventures, L.L.C., 130 Lytton
 Avenue,
Suite 220, Palo Alto, CA 94301

		
	PINNACLE VENTURES II-C, L.P.	  	 Pinnacle Ventures, L.L.C., 130 Lytton
 Avenue,
Suite 220, Palo Alto, CA 94301

			
		
	PINNACLE VENTURES II-R, L.P.	  	 Pinnacle Ventures, L.L.C., 130 Lytton
 Avenue,
Suite 220, Palo Alto, CA 94301

		
	Atul Sharma	  	 1406 Oakridge View Drive, Mableton, GA

30126

		
	Polaris Venture Partners V, L.P.	  	 1000 Winter Street, Suite 3350, Waltham,
 MA
02451

		
	Polaris Venture Partners Entrepreneurs’ Fund V, L.P.	  	 1000 Winter Street, Suite 3350, Waltham,
 MA
02451

		
	Polaris Venture Partners Founders’ Fund V, L.P.	  	 1000 Winter Street, Suite 3350, Waltham,
 MA
02451

		
	Polaris Venture Partners Special Founders’ Fund V, L.P.	  	 1000 Winter Street, Suite 3350, Waltham,
 MA
02451

		
	Baxter Healthcare Corporation	  	 One Baxter Parkway, Deerfield, Illinois

60015

		
	CHV II LP	  	 101 South Hanley Road, Suite 200, Clayton,
 MO
63105

 OCULAR THERAPEUTIX, INC. 

Amendment No. 1 to Fourth Amended and Restated 

Investor Rights Agreement 

This Amendment No. 1 (the “Amendment”) to the Fourth Amended and Restated Investor Rights Agreement, dated as of
May 31, 2013, by and among Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), the Founders (as defined in the Agreement) and the Investors (as defined in the Agreement) is entered into as of this 19th day of
June, 2014, among the Company and the Investors. 
 WHEREAS, the Company and the Investors desire to modify the terms of the Agreement; 

NOW THEREFORE, the Company and the Investors agree as follows: 

1. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Agreement. 

2. The definition of “Initial Public Offering” in Section 1 of the Agreement is hereby deleted in its entirety and the following definition
inserted in lieu thereof: 
 ““Initial Public Offering” means either (a) the sale of shares of
Common Stock to the public in an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, at a price of at least $5.50 per share (subject to appropriate adjustment for stock splits,
stock dividends, combinations and other similar recapitalizations affecting such shares), resulting in at least Thirty Million Dollars ($30,000,000) of gross proceeds to the Corporation, before deducting underwriting discounts and commissions and
other offering expenses or (b) any other underwritten public offering of shares of Common Stock deemed to be a Qualified IPO (as defined in Section 5.1 of the Sixth Amended and Restated Certificate of Incorporation, as amended) by the vote
or written consent of the holders of at least 60% of the then-outstanding shares of Preferred Stock.” 
 3. Except as specifically set forth herein, no
other portion of the Agreement shall be amended. 
 4. This Amendment may be executed in one or more counterparts, each of which shall for all purposes be
deemed to be an original and all of which shall constitute the same instrument. 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to the Fourth
Amended and Restated Investor Rights Agreement to be executed as of the day and year first written above. 
  

			
	COMPANY:
	
	OCULAR THERAPEUTIX, INC.
		
	By:	 	 /s/ Amarpreet Sawhney

	Name:	 	Amarpreet Sawhney
	Title:	 	President and CEO

 [Signature Page to Investor Rights Agreement Amendment] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to the Fourth
Amended and Restated Investor Rights Agreement to be executed as of the day and year first written above. 
 INVESTORS: 

 

			
	VERSANT VENTURE CAPITAL III, L.P.
		
	By:	 	 /s/ Charles Warden

	Name:	 	Charles Warden
	Title:	 	Managing Director
	
	VERSANT SIDE FUND III, L.P.
		
	By:	 	 /s/ Charles Warden

	Name:	 	Charles Warden
	Title:	 	Managing Director

 [Signature Page to Investor Rights Agreement Amendment] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to the Fourth
Amended and Restated Investor Rights Agreement to be executed as of the day and year first written above. 
  

			
	INVESTORS:
	
	POLARIS VENTURE PARTNERS V, L.P.
		
	By:	 	 /s/ John Gannon

	Name:	 	John Gannon
	Title:	 	Member
	
	POLARIS VENTURE PARTNERS ENTREPRENEURS’ FUND V, L.P.
		
	By:	 	 /s/ John Gannon

	Name:	 	John Gannon
	Title:	 	Member
	
	POLARIS VENTURE PARTNERS FOUNDERS’ FUND V, L.P.
		
	By:	 	 /s/ John Gannon

	Name:	 	John Gannon
	Title:	 	Member
	
	POLARIS VENTURE PARTNERS SPECIAL FOUNDERS’ FUND V, L.P.
		
	By:	 	 /s/ John Gannon

	Name:	 	John Gannon
	Title:	 	Member

 [Signature Page to Investor Rights Agreement Amendment] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to the Fourth
Amended and Restated Investor Rights Agreement to be executed as of the day and year first written above. 
  

			
	INVESTORS:
	
	SV LIFE SCIENCES FUND IV, L.P.
		
	By:	 	 /s/ Denise W. Marks

	Name:	 	Denise W. Marks
	Title:	 	SVLSF IV, LLC, Member
	
	SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L.P.
		
	By:	 	 /s/ Denise W. Marks

	Name:	 	Denise W. Marks
	Title:	 	SVLSF IV, LLC, Member

 [Signature Page to Investor Rights Agreement Amendment] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to the Fourth
Amended and Restated Investor Rights Agreement to be executed as of the day and year first written above. 
 INVESTORS: 

 

			
	SPARTA GROUP MA LLC SERIES 12
		
	By:	 	 /s/ Nirav Desai

	Name:	 	Nirav Desai
	Title:	 	Managing Director

 [Signature Page to Investor Rights Agreement Amendment] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to the Fourth
Amended and Restated Investor Rights Agreement to be executed as of the day and year first written above. 
  

			
	 INVESTORS:

	
	CHV II, L.P.
		
	By:	 	 /s/ Matthew I. Hermann

	Name:	 	 Matthew I. Hermann

	Title:	 	 Senior Managing Director

 [Signature Page to Investor Rights Agreement Amendment] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to the Fourth Amended and
Restated Investor Rights Agreement to be executed as of the day and year first written above. 
  

			
	INVESTORS:
	
	BAXTER HEALTHCARE CORPORATION
		
	By:	 	 /s/ Stephanie D. Miller

	Name:	 	 Stephanie D. Miller

	Title:	 	 Assistant Secretary

 [Signature Page to Investor Rights Agreement Amendment] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to the Fourth
Amended and Restated Investor Rights Agreement to be executed as of the day and year first written above. 
 INVESTORS: 

 

			
	INCEPT, LLC
		
	By:	 	 /s/ Amarpreet Sawhney

	Name:	 	Amarpreet Sawhney
	Title:	 	General Partner
	
	JASWINDER CHADHA 2007 DELAWARE TRUST
		
	By:	 	 /s/ Amarpreet Sawhney

	Name:	 	Amarpreet Sawhney
	Title:	 	Trustee
	
	NAVDEEP CHADHA 2007 DELAWARE TRUST
		
	By:	 	 /s/ Amarpreet Sawhney

	Name:	 	Amarpreet Sawhney
	Title:	 	Trustee

 [Signature Page to Investor Rights Agreement Amendment]EX-10.1

 Exhibit 10.1 

OCULAR THERAPEUTIX, INC. 

2006 STOCK INCENTIVE PLAN, AS AMENDED 
  

	1.	DEFINITIONS. 

 Unless otherwise specified or unless the context otherwise requires, the
terms set forth on Exhibit A—Definitions, shall have the meanings used therein. 
  

	2.	PURPOSES OF THE PLAN. 

 The Plan is intended to encourage ownership of Shares by Key
Employees and by directors of and consultants to the Company, its Affiliates and Strategic Partners in order to attract such people, to induce them to work for the benefit of the Company and its Affiliates and to provide incentive for them to
promote the success of the Company and its Affiliates. The Plan provides for the granting of ISOs, Non-Qualified Options and Stock Grants. 
  

	3.	SHARES SUBJECT TO THE PLAN. 

 (a) The maximum number of Shares which shall be reserved
and available for Stock Rights pursuant to this Plan shall be 7,527,417 shares, subject to adjustment in accordance with Paragraph 16 hereof. Shares issued under the Plan may be authorized but unissued shares of Common Stock or shares of Common
Stock held in treasury. 
 (b) To the extent that any Option shall lapse, terminate, expire or otherwise be cancelled without the issuance of
Shares, or if the Company shall reacquire any Shares issued pursuant to a Stock Grant, the Shares shall be available for the granting of other Stock Rights under the Plan. 

(c) Shares issuable under the Plan may be subject to such restrictions on transfer, repurchase rights or other restrictions as shall be
determined by the Administrator. 
  

	4.	ADMINISTRATION OF THE PLAN. 

 (a) At the discretion of the Company’s Board of
Directors, the Administrator of the Plan shall be either (i) by the full Board of Directors of the Company or (ii) by a committee (the “Committee”) consisting of two or more members of the Company’s Board of Directors. In
the event the full Board of Directors is the Administrator of the Plan, references herein to the Committee shall be deemed to mean the full Board of Directors. The Board of Directors may from time to time appoint a member or members of the Committee
in substitution for or in addition to the member or members then in office and may fill vacancies on the Committee however caused. The Committee may choose one of its members as Chairman and shall hold meetings at such times and places as it shall
deem advisable. A majority of the members of the Committee shall constitute a quorum and any action may be taken by a majority of those present and voting at any meeting. 

  
 Page 1 of 19 

 (b) Any action may also be taken without the necessity of a meeting by a written instrument
signed by a majority of the Committee. The decision of the Committee as to all questions of interpretation and application of the Plan shall be final, binding and conclusive on all persons. The Committee shall have the authority to adopt, amend and
rescind such rules and regulations as, in its opinion, may be advisable in the administration of the Plan. The Committee may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in any Option Agreement or Stock
Grant Agreement in the manner and to the extent it shall deem expedient to carry the Plan into effect and shall be the sole and final judge of such expediency. No Committee member shall be liable for any action or determination made in good faith.

 (c) Subject to the terms of the Plan, the Administrator is authorized to: 

i. Interpret the provisions of the Plan or of any Option or Stock Grant and to make all rules and determinations which it deems necessary or
advisable for the administration of the Plan; 
 ii. Determine which persons shall be considered eligible Participants in the Plan and which
of such eligible persons shall be granted Stock Rights; 
 iii. Determine the number of Shares for which Stock Rights shall be granted; and

 iv. Specify the terms and conditions upon which Stock Rights may be granted, including, but not limited to, the time or times when Stock
Rights may be granted, shall become exercisable and the duration of the exercise period, and the price of Shares subject to each Stock Right. 

Notwithstanding the foregoing, all such interpretations, rules, determinations, terms and conditions shall be made and prescribed in the context of preserving
the tax status under Section 422 of the Code of those Options which are designated as ISOs. Subject to the foregoing, the interpretation and construction by the Administrator of any provisions of the Plan or of any Stock Right shall be final,
unless otherwise determined by the Board of Directors, if the Administrator is the Committee. 
  

	5.	ELIGIBILITY FOR PARTICIPATION. 

 The Administrator will, in its sole discretion, name the
Participants in the Plan, provided, however, that each Participant must be a Key Employee, director or consultant of the Company, an Affiliate, or of a Strategic Partner at the time a Stock Right is granted. Notwithstanding the foregoing, the
Administrator may authorize the grant of a Stock Right to a person not then an employee, director or consultant of the Company or of an Affiliate; provided, however, that the actual grant of such Stock Right shall be conditioned upon such person
becoming eligible to become a Participant at or prior to the time of the delivery of the Agreement evidencing such Stock Right. ISOs may be granted only to Key Employees. Non-Qualified Options and Stock Grants may be granted to any Key Employee,
director or consultant of the Company, an Affiliate or Strategic Partner or any other eligible Participant. The granting of any Stock Right to any individual shall neither entitle that individual to, nor disqualify him or her from, participation in
any other grant of Stock Rights. 

  
 Page 2 of 19 

 In determining the eligibility of an individual to be granted an Option or Stock Grant, as well
as in determining the number of Shares to be optioned or granted to any individual, the Administrator shall take into account the position and responsibilities of the individual being considered, the nature and value to the Company or an Affiliate
of his or her service and accomplishments, his or her present and potential contribution to the success of the Company or an Affiliate, and such other factors as the Committee may deem relevant. 

No Option designated as an ISO shall be granted to any Key Employee of the Company or an Affiliate if such Key Employee owns, immediately
prior to the grant of an Option, stock representing more than 10% of the combined voting power of all classes of stock of the Company or an Affiliate, unless the purchase price for the stock under such Option shall be at least 110% of its Fair
Market Value at the time such Option is granted and the Option, by its terms, shall not be exercisable more than five years from the date it is granted. In determining the stock ownership under this paragraph, the provisions of Section 424(d)
of the Code shall be controlling. 
 Subject to the provisions hereof relating to adjustments upon changes in the shares of Common Stock, no
employee shall be eligible to be granted Options covering more than 1,000,000 shares of Common Stock during any calendar year, except that this restriction shall not apply at any time prior to the date on which the Company lists any shares of its
securities on any securities exchange. The restriction contained in this paragraph shall also not apply until the earliest of: (1) the first material modification of the Plan (including any increase in the number of shares of Common Stock
reserved for issuance hereunder); (2) the issuance of all of the shares of Common Stock reserved for issuance under the Plan; (3) the expiration of the Plan; (4) the first meeting of stockholders at which Directors are to be elected
that occurs after the close of the third (3rd) calendar year following the calendar year in which occurred the first registration of an equity security by the Company under Section 12 of the Securities Act of 1934, as amended; or
(5) such other date required by Section 162(m) of the Code. 
  

	6.	TERMS AND CONDITIONS OF OPTIONS. 

 Each Option shall be set forth in writing in an Option
Agreement, duly executed on behalf of the Company and by the Participant to whom such Option is granted. The Administrator may provide that Options be granted subject to such terms and conditions, consistent with the terms and conditions
specifically required under this Plan, as the Administrator may deem appropriate including, without limitation, subsequent approval by the shareholders of the Company of this Plan or any amendments thereto. 

(a) Non-Qualified Options: Each Option intended to be a Non-Qualified Option shall be subject to the terms and conditions which the
Administrator determines to be appropriate and in the best interest of the Company, subject to the following minimum standards for any such Non-Qualified Option: 

(i) Option Price: Each Option Agreement shall state the option price (per Share) of the Shares covered by each Option, which option price shall
be determined by the Administrator but shall not be less than the par value per share of Common Stock. 
 (ii) Each Option Agreement shall
state the number of Shares to which it pertains; 

  
 Page 3 of 19 

 (iii) Each Option Agreement shall state the date or dates on which it first is exercisable and
the date after which it may no longer be exercised, and may provide that the Option rights accrue or become exercisable in installments over a period of months or years, or upon the occurrence of certain conditions or the attainment of stated goals
or events; and 
 (iv) Exercise of any Option may be conditioned upon the Participant’s execution of certain agreements in form
satisfactory to the Administrator providing for certain protections for the Company and its shareholders including, without limitation, requirements that: 
  

	 	A.	The Participant’s or the Participant’s Survivors’ right to sell or transfer the Shares may be restricted; and 

  

	 	B.	The Participant or the Participant’s Survivors may be required to execute letters of investment intent and must also acknowledge that the Shares will bear legends noting any applicable restrictions.

 (b) ISOs: Each Option intended to be an ISO shall be issued only to a Key Employee of the Company (and not any other
person including a Key Employee of a Strategic Partner) and shall be subject to the following terms and conditions and to such additional restrictions or changes as the Administrator determines are appropriate but that are not in conflict with
Section 422 of the Code: 
 (i) Minimum standards: The ISO shall meet the minimum standards required of Non-Qualified Options, as
described in Paragraph 6(a) above, except clause (i) thereunder. 
 (ii) Option Price: Immediately before the Option is granted, if the
Participant owns, directly or by reason of the applicable attribution rules in Section 424(d) of the Code: 
  

	 	A.	Ten percent (10%) or less of the total combined voting power of all classes of stock of the Company or an Affiliate, the Option price per share of the Shares covered by each Option shall not be less than one
hundred percent (100%) of the Fair Market Value per share of the Shares on the date of the grant of the Option as determined by the Administrator in accordance with Section 422 of the Code. 

 

	 	B.	More than ten percent (10%) of the total combined voting power of all classes of stock of the Company or an Affiliate, the Option price per share of the Shares covered by each Option shall not be less than one
hundred ten percent (110%) of the said Fair Market Value on the date of grant. 

 (iii) Term of Option: For Participants
who own: 
  

	 	A.	Ten percent (10%) or less of the total combined voting power of all classes of stock of the Company or an Affiliate, each Option shall terminate not more than ten (10) years from the date of the grant or at
such earlier time as the Option Agreement may provide. 

  
 Page 4 of 19 

	 	B.	More than ten percent (10%) of the total combined voting power of all classes of stock of the Company or an Affiliate, each Option shall terminate not more than five (5) years from the date of the grant or at
such earlier time as the Option Agreement may provide. 

 (iv) Limitation on Yearly Exercise: The Option Agreements shall
restrict the amount of Options which may be exercisable in any calendar year (under this or any other ISO plan of the Company or an Affiliate) so that the aggregate Fair Market Value (determined at the time each ISO is granted) of the stock with
respect to which ISOs are exercisable for the first time by the Participant in any calendar year does not exceed one hundred thousand dollars ($100,000), provided that this subparagraph (d) shall have no force or effect if its inclusion in the
Plan is not necessary for Options issued as ISOs to qualify as ISOs pursuant to Section 422(d) of the Code. 
  

	7.	TERMS AND CONDITIONS OF STOCK GRANTS. 

 Each offer of a Stock Grant to a Participant
shall state the date prior to which the Stock Grant must be accepted by the Participant, and the principal terms of each Stock Grant shall be set forth in a Stock Grant Agreement, duly executed by the Company and the Participant. The Stock Grant
Agreement shall be in a form approved by the Administrator and shall contain terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company, subject to the following minimum standards: 

(a) Each Stock Grant Agreement shall state the purchase price (per share), if any, of the Shares covered by each Stock Grant, which purchase
price shall be determined by the Administrator but shall not be less than the par value on the date of the grant of the Stock Grant; 
 (b)
Each Stock Grant Agreement shall state the number of Shares to which the Stock Grant pertains; and 
 (c) Each Stock Grant Agreement shall
include the terms of any right of the Company to reacquire the Shares subject to the Stock Grant, including the time and events upon which such rights shall accrue and the purchase price therefor, if any. 

 

	8.	EXERCISE OF OPTIONS AND ISSUE OF SHARES. 

 To the extent that the right to purchase
Shares under an Option has accrued and is in effect, an Option (or any part or installment thereof) shall be exercised by giving written notice to the Company at its principal executive office, together with payment of the full purchase price in
accordance with this Paragraph for the Shares as to which the Option is being exercised, and upon compliance with any other condition(s) set forth in the Option Agreement. Such written notice shall be signed by the person exercising the Option,
shall state the number of Shares with respect to which the Option is being exercised and shall contain any representation required by the Plan or the Option Agreement. 

  
 Page 5 of 19 

 Each Option granted under the Plan shall, subject to the other provisions of this Plan, be
exercisable at such time or times and during such period as shall be set forth in the Option Agreement. 
 To the extent that an Option to
purchase shares is not exercised by a Participant when it becomes initially exercisable, it shall not expire but shall be carried forward and shall be exercisable, on a cumulative basis, until the expiration of the exercise period. No partial
exercise may be made for less than one hundred (100) full shares of Common Stock. 
 Payment of the purchase price for the Shares as to
which such Option is being exercised shall be made (a) in United States dollars in cash or by check, or (b) at the discretion of the Administrator, and so long as there is no adverse tax or accounting impact to the Company, through
delivery of shares of Common Stock owned by the Participant for at least six (6) months and having a Fair Market Value equal as of the date of the exercise to the cash exercise price of the Option, or (c) at the discretion of the
Administrator, by delivery of the grantee’s personal recourse note bearing interest at a fair market interest rate in accordance with applicable accounting practice for such note, or at 100% of the applicable Federal rate (“AFR”), as
defined in Section 1274(d) of the Code, if the AFR is greater than a fair market interest rate, or (d) at the discretion of the Administrator, by any combination of (a), (b) and (c) above. 

When an Option is exercised, the Company shall then reasonably promptly deliver the Shares as to which such Option was exercised to the
Participant (or to the Participant’s Survivors, as the case may be). In determining what constitutes “reasonably promptly,” it is expressly understood that the issuance and delivery of the Shares may be delayed by the Company in order
to comply with any law or regulation (including, without limitation, state securities or “blue sky” laws) which requires or makes it desirable for the Company to take any action with respect to the Shares prior to their issuance. The
Shares shall, upon delivery, be evidenced by an appropriate certificate or certificates for fully paid, non-assessable Shares. 
 The
Administrator shall have the right to accelerate the date of exercise of any installment of any Option; provided that the Administrator shall not accelerate the exercise date of any installment of any Option granted as an ISO (and not previously
converted into a Non-Qualified Option pursuant to Paragraph 26) if such acceleration would violate any vesting limitation contained in Section 422(d) of the Code. 

The Administrator may, in its discretion, amend any term or condition of an outstanding Option provided (i) such amendment is permitted
by the Plan, (ii) any such amendment shall be made only with the consent of the Participant to whom the Option was granted, or in the event of the death of the Participant, the Participant’s Survivors, if the amendment is adverse to the
Participant, and (iii) any such amendment of any ISO shall be made only after the Administrator, after consulting the counsel for the Company, determines whether such amendment would constitute a “modification” of any Option which is
an ISO (as that term is defined in Section 424(h) of the Code) or would cause any adverse tax consequences for the holder of such ISO. 

  
 Page 6 of 19 

	9.	ACCEPTANCE OF STOCK GRANT AND ISSUE OF SHARES. 

 A Stock Grant (or any part or
installment thereof) shall be accepted by executing the Stock Grant Agreement and delivering it to the Company at its principal office, together with payment of the full purchase price, if any, in accordance with this Paragraph for the Shares as to
which such Stock Grant is being accepted, and upon compliance with any other conditions set forth in the Stock Grant Agreement. Payment of the purchase price for the Shares as to which such Stock Grant is being accepted shall be made (a) in
United States dollars in cash or by check, or (b) at the discretion of the Administrator and only so long as there is no adverse tax or accounting impact to the Company, through delivery of shares of Common Stock owned by the Participant for at
least six (6) months and having a fair market value equal as of the date of acceptance of the Stock Grant to the purchase price of the Stock Grant determined in good faith by the Administrator, or (c) at the discretion of the
Administrator, by delivery of the grantee’s personal recourse note bearing interest at a fair market interest rate in accordance with applicable accounting practice for such note, or at 100% of the applicable Federal rate (“AFR”), as
defined in Section 1274(d) of the Code, if the AFR is greater than a fair market interest rate, or (d) at the discretion of the Administrator, by any combination of (a), (b) and (c) above. 

The Company shall then reasonably promptly (as determined in paragraph 8 above) deliver the Shares as to which such Stock Grant was accepted
to the Participant (or to the Participant’s Survivors, as the case may be), subject to any escrow provision set forth in the Stock Grant Agreement. 

The Administrator may, in its discretion, amend any term or condition of an outstanding Stock Grant or Stock Grant Agreement provided
(i) such amendment is permitted by the Plan, and (ii) any such amendment shall be made only with the consent of the Participant to whom the Stock Grant was made, if the amendment is adverse to the Participant. 

 

	10.	RIGHTS AS A SHAREHOLDER. 

 No Participant to whom a Stock Right has been granted shall
have rights as a shareholder with respect to any Shares covered by such Stock Right, except after: (a) due exercise of the Option or acceptance of the Stock Grant in compliance with the terms of the Stock Right and tender of the full purchase
price, if any, for the Shares being purchased pursuant to such exercise or acceptance; and (b) registration of the Shares in the Company’s share register in the name of the Participant. 

 

	11.	ASSIGNABILITY AND TRANSFERABILITY OF STOCK RIGHTS. 

 By its terms, a Stock Right granted
to a Participant shall not be assignable or transferable by the Participant other than (i) by will or by the laws of descent and distribution, except that an optionee may transfer Stock Rights that are not ISOs granted under the Plan to the
Participant’s spouse or children or to a trust or partnership for the benefit of the Participant or Participant’s spouse or children, or (ii) as otherwise determined by the Administrator and set forth in the applicable Option
Agreement or Stock Grant Agreement. The designation of a beneficiary of a Stock Right by a Participant shall not be deemed a transfer prohibited by this Paragraph. Except as provided above, a Stock Right shall only be exercisable or may only be
accepted, during the Participant’s lifetime, by such Participant (or by his or her legal representative) and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to
execution, attachment or similar process. Any Stock Right granted under the Plan shall be null and void and without effect upon the bankruptcy of the Participant to whom the Stock Right is granted, or upon any attempted transfer, assignment, pledge,
hypothecation or other disposition except as herein provided, including without limitation any disposition, attachment, divorce, trustee process or similar process, whether legal or equitable upon such Stock Right. 

  
 Page 7 of 19 

	12.	EFFECT ON OPTIONS OF TERMINATION OF SERVICE. 

 (a) Termination Other Than “For
Cause”, Death or Disability. Except as otherwise provided in the pertinent Option Agreement, in the event of a termination of service (whether as an employee, director or consultant) with the Company or an Affiliate before the Participant
has exercised an Option, the following rules apply: 
 (i) A Participant who ceases to be an employee, director or consultant of the Company
or of an Affiliate (for any reason other than termination “for cause”, Disability, or death for which events there are special rules in Subparagraphs B, C and D, respectively), may exercise any Option granted to him or her to the extent
that the Option is exercisable on the date of such termination of service, but only within such term as the Administrator has designated in the pertinent Option Agreement. Notwithstanding the above, however, regarding any Shares purchased upon the
exercise of the Option, the Company shall maintain the repurchase rights set forth in section 13 regarding vested Shares. 
 (ii) Except as
provided elsewhere in this Paragraph, in no event may an Option Agreement provide, if an Option is intended to be an ISO, that the time for exercise be later than three (3) months after the Participant’s termination of employment. 

(iii) The provisions of this Paragraph, and not the provisions of subparagraph C or D, shall apply to a Participant who subsequently becomes
Disabled or dies after the termination of employment, director status or consultancy, provided, however, in the case of a Participant’s Disability or death within three (3) months after the termination of employment, director status or
consultancy, the Participant or the Participant’s Survivors may exercise the Option within one (1) year after the date of the Participant’s termination of employment, but in no event after the date of expiration of the term of the
Option. 
 (iv) Notwithstanding anything herein to the contrary, if subsequent to a Participant’s termination of employment, termination
of director status or termination of consultancy, but prior to the exercise of an Option, the Board of Directors determines that, either prior or subsequent to the Participant’s termination, the Participant engaged in conduct which would
constitute “cause”, then such Participant shall forthwith cease to have any right to exercise any Option. 
 (v) A Participant to
whom an Option has been granted under the Plan who is absent from work with the Company or with an Affiliate because of temporary disability (any disability other than a Disability), or who is on leave of absence for any purpose, shall not, during
the period of any such absence, be deemed, by virtue of such absence alone, to have terminated such Participant’s employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise
expressly provide. 
 (vi) Except as required by law or as set forth in the pertinent Option Agreement, Options granted under the Plan shall
not be affected by any change of a Participant’s status within or among the Company and any Affiliates, so long as the Participant continues to be an employee, director or consultant of the Company or any Affiliate. 

  
 Page 8 of 19 

 (b) Termination For Cause. Except as otherwise provided in the pertinent Option Agreement,
the following rules apply if the Participant’s service (whether as an employee, director or consultant) with the Company or an Affiliate is terminated “for cause”: 

(i) All outstanding and unexercised Options as of the time the Participant is notified his or her service is terminated “for cause”,
whether vested or unvested, will immediately be forfeited and the Company shall have the right to repurchase all Shares previously issued to the Participant upon exercise by the Participant of Options at a purchase price per Share equal to the per
Share Option price paid by the Participant upon exercise of such options. 
 (ii) For purposes of this Plan, “cause” shall include
(and is not limited to) dishonesty with respect to the Company or any Affiliate, breach of fiduciary duty, insubordination, substantial malfeasance or non-feasance of duty, unauthorized disclosure of confidential information, material failure or
refusal to comply with Company’s published policies generally applicable to all employees, and conduct materially harmful to the business of the Company or any Affiliate. The determination of the Administrator as to the existence of
“cause” will be conclusive on the Participant and the Company. 
 (iii) “Cause” is not limited to events which have
occurred prior to a Participant’s termination of service, nor is it necessary that the Administrator’s finding of “cause” occur prior to termination. If the Administrator determines, subsequent to a Participant’s termination
of service but prior to the exercise of an Option, that either prior or subsequent to the Participant’s termination the Participant engaged in conduct which would constitute “cause”, then the right to exercise any Option is forfeited.

 (iv) Any definition in an agreement between the Participant and the Company or an Affiliate, which contains a conflicting definition of
“cause” for termination and which is in effect at the time of such termination, shall supersede the definition in this Plan with respect to such Participant. 

(c) Termination for Disability. Except as otherwise provided in the pertinent Option Agreement, a Participant who ceases to be an
employee, director or consultant of the Company or of an Affiliate by reason of Disability may exercise any Option granted to such Participant: 

(i) To the extent exercisable but not exercised on the date of Disability; and 

(ii) In the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion of any additional rights as would have
accrued had the Participant not become Disabled prior to the end of the accrual period which next ends following the date of Disability. The proration shall be based upon the number of days of such accrual period prior to the date of Disability.

 A Disabled Participant may exercise such rights only within the period ending one (1) year after the date of the Participant’s
termination of employment, directorship or consultancy, as the case may be, notwithstanding that the Participant might have been able to exercise the Option as to some or all of the Shares on a later date if the Participant had not become Disabled
and had continued to be an employee, director or consultant or, if earlier, within the originally prescribed term of the Option. 

  
 Page 9 of 19 

 (d) Termination Due to Death. Except as otherwise provided in the pertinent Option
Agreement, in the event of the death of a Participant while the Participant is an employee, director or consultant of the Company or of an Affiliate, such Option may be exercised by the Participant’s Survivors: 

(i) To the extent exercisable but not exercised on the date of death; and 

(ii) In the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion of any additional rights which would
have accrued had the Participant not died prior to the end of the accrual period which next ends following the date of death. The proration shall be based upon the number of days of such accrual period prior to the Participant’s death. 

If the Participant’s Survivors wish to exercise the Option, they must take all necessary steps to exercise the Option within one
(1) year after the date of death of such Participant, notwithstanding that the decedent might have been able to exercise the Option as to some or all of the Shares on a later date if he or she had not died and had continued to be an employee,
director or consultant or, if earlier, within the originally prescribed term of the Option. 
  

	13.	EFFECT OF TERMINATION OF SERVICE ON STOCK GRANTS. 

 (a) General. In the event of a
termination of service (whether as an employee, director or consultant) with the Company or an Affiliate for any reason before the Participant has accepted the offer of, and complied with all purchase or acquisition requirements under, a Stock Grant
in accordance with its terms, such offer of a Stock Grant shall terminate. 
 For purposes of this Paragraph 13, a Participant to whom a
Stock Grant has been offered under the Plan who is absent from work with the Company or with an Affiliate because of temporary disability (any disability other than a “Disability”), or who is on leave of absence for any purpose, shall not,
during the period of any such absence, be deemed, by virtue of such absence alone, to have terminated such Participant’s employment, director status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise
expressly provide. 
 In addition, for purposes of this Paragraph 13, any change of employment or other service within or among the Company
and any Affiliates shall not be treated as a termination of employment, director status or consultancy so long as the Participant continues to be an employee, director or consultant of the Company or any Affiliate. 

Except as otherwise provided in the pertinent Stock Grant Agreement, in the event of a termination of service (whether as an employee,
director or consultant), other than termination “for cause,” Disability, or death for which events there are special rules in subparagraphs B, C, and D, the Company shall have the right to repurchase all unvested Shares at the original
purchase price. Further, the vested Shares may be repurchased by the Company, at its sole option and upon notice to Participant within ninety (90) days of the date of termination of employment of such Participant, for a price equal to
(i) the valuation of the Shares as determined 

  
 Page 10 of 19 

 
in connection with the most recent equity financing, the grant of Options or issuance of Shares to Participants or in consideration for an acquisition or joint venture, if any, occurring within
the six (6) months prior to such termination (each a “Valuation Event”), or (ii), if no Valuation Event has occurred within six (6) months, the valuation set by the Administrator, in its discretion (an “Administrator
Valuation”). Such notice shall set forth the valuation of such Shares and the intended date of closing (the “Call Notice”). If the valuation is set by an Administrator Valuation, the Participant may, within ten (10) days of the
Call Notice, object in writing to such valuation as set forth in the Call Notice and request that an independent business valuation expert be appointed to provide a separate valuation. In such case, the fair market value shall promptly be determined
by an independent valuation expert selected by the Participant from a group of three (3) experts recommended in writing by the Company within ten (10) days of receipt by the Company of the written objection by the Participant. The parties
shall be bound by the determination of such expert. All costs of any appraisal hereunder shall be paid by the Participant, except to the extent that the valuation set by the arbitrator exceeds the Administrator Valuation by 10% or more. In the
latter case, the costs of the arbitrator shall be paid by the Company. To the extent an appraisal is requested, the closing shall occur promptly upon the completion of the appraisal. 

(b) Termination For Cause. Except as otherwise provided in the pertinent Stock Grant Agreement, upon a termination of employment for
cause, all Shares subject to any Stock Grant shall be immediately subject to repurchase by the Company at the purchase price, if any, thereof. For all purposes of this Plan, including this paragraph 13, “cause” shall have the meanings used
in and shall be determined as provided in paragraph 12. 
 (c) Termination Due to Disability. Except as otherwise provided in the
pertinent Stock Grant Agreement, if a Participant ceases to be an employee, director or consultant of the Company or of an Affiliate by reason of Disability, the Company and shall have the right to purchase all unvested Shares at the original
purchase price, to the extent such rights of repurchase are to lapse periodically after the date of Disability, such rights of repurchase shall lapse on a pro rata portion of the Shares subject to such Stock Grant as would have lapsed had the
Participant not become Disabled prior to the end of the vesting period which next ends following the date of Disability. The proration shall be based upon the number of days of such vesting period prior to the date of Disability. 

(d) Termination Due to Death. Except as otherwise provided in the pertinent Stock Grant Agreement in the event of the death of a
Participant while the Participant is an employee, director or consultant of the Company or of an Affiliate, the Company shall have the right to repurchase unvested Shares at the original purchase price. To the extent such rights of repurchase are to
lapse periodically after the date of death, such rights of repurchase shall lapse on a pro rata portion of the Shares subject to such Stock Grant as would have lapsed had the Participant not died prior to the end of the vesting period following the
date of death. The proration shall be based upon the number of days of such vesting period prior to the Participant’s death. 
  

	14.	PURCHASE FOR INVESTMENT. 

 Unless the offering and sale of the Shares to be issued upon
the particular exercise or acceptance of a Stock Right shall have been effectively registered under the Securities Act of 1933, as now in force or hereafter amended (the “1933 Act”), the Company shall be under no obligation to issue the
Shares covered by such exercise unless and until the following conditions have been fulfilled: 

  
 Page 11 of 19 

 (a) The person(s) who exercise(s) or accept(s) such Stock Right shall warrant to the Company,
prior to the receipt of such Shares, that such person(s) are acquiring such Shares for their own respective accounts, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the
person(s) acquiring such Shares shall be bound by the provisions of the following legend which shall be endorsed upon the certificate(s) evidencing their Shares issued pursuant to such exercise or such grant: 

“The shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any
person, including a pledgee, unless (1) either (a) a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or (b) the Company shall have received an opinion of counsel
satisfactory to it that an exemption from registration under such Act is then available, and (2) there shall have been compliance with all applicable state securities laws.” 

(b) At the discretion of the Administrator, the Company shall have received an opinion of its counsel that the Shares may be issued upon such
particular exercise or acceptance in compliance with the 1933 Act without registration thereunder. 
  

	15.	DISSOLUTION OR LIQUIDATION OF THE COMPANY. 

 Upon the dissolution or liquidation of the
Company, all Options granted under this Plan which as of such date shall not have been exercised and all Stock Grants which have not been accepted will terminate and become null and void; provided, however, that if the rights of a Participant or a
Participant’s Survivors have not otherwise terminated and expired, the Participant or the Participant’s Survivors will have the right immediately prior to such dissolution or liquidation to exercise or accept any Stock Right to the extent
that the Stock Right is exercisable or subject to acceptance as of the date immediately prior to such dissolution or liquidation. 
  

	16.	ADJUSTMENTS. 

 Upon the occurrence of any of the following events, a Participant’s
rights with respect to any Stock Right granted to him or her hereunder shall be adjusted as hereinafter provided, unless otherwise specifically provided in the pertinent Option Agreement or Stock Grant Agreement: 

(a) Stock Dividends and Stock Splits. If (i) the shares of Common Stock shall be subdivided or combined into a greater or smaller
number of shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii) additional shares or new or different shares or other securities of the Company or other non-cash assets are
distributed with respect to such shares of Common Stock, the number of shares of Common Stock deliverable upon the exercise or acceptance of such Stock Right shall be appropriately increased or decreased proportionately, and appropriate adjustments
shall be made in the purchase price per share to reflect such events. 

  
 Page 12 of 19 

 (b) Consolidations or Mergers. In the event of (i) any merger, consolidation, sale of
all or substantially all of the business or assets of the Company or any sale or issuance of stock, in a single or related series of transactions, where the number of shares of voting stock outstanding immediately before the effective date of such
transaction are converted into, exchanged for or represent less than 50% percent of the voting stock of the surviving or resulting company immediately after such transaction, or (ii) the acquisition by any “person” (as such term is
used in Sections 13(d)(3) and 14(d)(2) of the Securities Exchange Act of 1934) of beneficial ownership, directly or indirectly, of securities of the Company representing 50.1% or more of the combined voting power of the Company’s then
outstanding securities other than as a result of the purchase of equity securities directly from the Company in connection with a financing transaction, provided, however, such events shall not include any transaction where shares of the
Company’s capital stock are sold or otherwise issued as part of an equity financing of the Company (any such event provided for in subsection (i) or (ii), an “Acquisition”), the Administrator or the board of directors of any
entity assuming the obligations of the Company hereunder (the “Successor Board”), shall, as to outstanding Options, either (x) make appropriate provision for the continuation of such Options by substituting on an equitable basis for
the Shares then subject to such Options either the consideration payable with respect to the outstanding shares of Common Stock in connection with the Acquisition or securities of any successor or acquiring entity; or (y) upon written notice to
the Participants, provide that all Options must be exercised (to the extent then exercisable after taking into account any applicable acceleration of vesting) at the end of which period the Options shall terminate; or (z) terminate all Options
in exchange for a cash payment equal to the excess of the Fair Market Value of the Shares subject to such Options (to the extent then exercisable after taking into account any applicable acceleration of vesting) over the exercise price thereof. 

With respect to outstanding Stock Grants, the Administrator or the Successor Board, shall either (i) make appropriate provisions for the
continuation of such Stock Grants by substituting on an equitable basis for the Shares then subject to such Stock Grants either the consideration payable with respect to the outstanding Shares of Common Stock in connection with the Acquisition or
securities of any successor or acquiring entity; or (ii) upon written notice to the Participants, provide that all Stock Grants must be accepted (to the extent then subject to acceptance) within a specified number of days of the date of such
notice, at the end of which period the offer of the Stock Grants shall terminate; or (iii) terminate all Stock Grants in exchange for a cash payment equal to the excess of the Fair Market Value of the Shares subject to such Stock Grants over
the purchase price thereof, if any. In addition, in the event of an Acquisition, the Administrator may waive any or all Company repurchase rights with respect to outstanding Stock Grants. 

(c) Recapitalization or Reorganization. In the event of a recapitalization or reorganization of the Company (other than a transaction
described in Subparagraph B above) pursuant to which securities of the Company or of another corporation are issued with respect to the outstanding shares of Common Stock, a Participant upon exercising or accepting a Stock Right shall be
entitled to receive, for the purchase price, if any, paid upon such exercise or acceptance, the securities which would have been received if such Stock Right had been exercised or accepted prior to such recapitalization or reorganization. 

  
 Page 13 of 19 

 (d) Modification of ISOs. Notwithstanding the foregoing, any adjustments made pursuant to
Subparagraph A, B or C with respect to ISOs shall be made only after the Administrator, after consulting with counsel for the Company, determines whether such adjustments would constitute a “modification” of such ISOs (as that term is
defined in Section 424(h) of the Code) or would cause any adverse tax consequences for the holders of such ISOs. If the Administrator determines that such adjustments made with respect to ISOs would constitute a modification of such ISOs, it
may refrain from making such adjustments, unless the holder of an ISO specifically requests in writing that such adjustment be made and such writing indicates that the holder has full knowledge of the consequences of such “modification” on
his or her income tax treatment with respect to the ISO. 
  

	17.	ISSUANCES OF SECURITIES. 

 Except as expressly provided herein, no issuance by the
Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares subject to Stock Rights. Except as
expressly provided herein, no adjustments shall be made for dividends paid in cash or in property (including without limitation, securities) of the Company prior to any issuance of Shares pursuant to a Stock Right. 

 

	18.	FRACTIONAL SHARES. 

 No fractional shares shall be issued under the Plan and the person
exercising a Stock Right shall receive from the Company cash in lieu of such fractional shares equal to the Fair Market Value thereof. 
  

	19.	CONVERSION OF ISOs INTO NON-QUALIFIED OPTIONS; TERMINATION OF ISOs. 

 The Administrator,
at the written request of any Participant, may in its discretion take such actions as may be necessary to convert such Participant’s ISOs (or any portions thereof) that have not been exercised on the date of conversion into Non-Qualified
Options at any time prior to the expiration of such ISOs, regardless of whether the Participant is an employee of the Company or an Affiliate at the time of such conversion. Such actions may include, but not be limited to, extending the exercise
period or reducing the exercise price of the appropriate installments of such Options. At the time of such conversion, the Administrator (with the consent of the Participant) may impose such conditions on the exercise of the resulting Non-Qualified
Options as the Administrator in its discretion may determine, provided that such conditions shall not be inconsistent with this Plan. Nothing in the Plan shall be deemed to give any Participant the right to have such Participant’s ISOs
converted into Non-Qualified Options, and no such conversion shall occur until and unless the Administrator takes appropriate action. The Administrator, with the consent of the Participant, may also terminate any portion of any ISO that has not been
exercised at the time of such conversion. 
  

	20.	WITHHOLDING. 

 In the event that any federal, state, or local income taxes, employment
taxes, Federal Insurance Contributions Act (“F.I.C.A.”) withholdings or other amounts are required by applicable law or governmental regulation to be withheld from the Participant’s salary, wages or other remuneration in connection
with the exercise or acceptance of a Stock Right or in connection with a Disqualifying Disposition (as defined in Paragraph 21) or upon the lapsing of any right of repurchase, the Company may withhold from the Participant’s compensation, if
any, 

  
 Page 14 of 19 

 
or may require that the Participant advance in cash to the Company, or to any Affiliate of the Company which employs or employed the Participant, the amount of such withholdings unless a
different withholding arrangement, including the use of shares of the Company’s Common Stock or a promissory note, is authorized by the Administrator (and permitted by law). For purposes hereof, the fair market value of the shares withheld for
purposes of payroll withholding shall be determined in the manner provided in Paragraph 1 above, as of the most recent practicable date prior to the date of exercise and shall not exceed the minimum amount required by law to be withheld. If the fair
market value of the shares withheld is less than the amount of payroll withholdings required, the Participant may be required to advance the difference in cash to the Company or the Affiliate employer. The Administrator in its discretion may
condition the exercise of an Option for less than the then Fair Market Value on the Participant’s payment of such additional withholding. 
  

	21.	NOTICE TO COMPANY OF DISQUALIFYING DISPOSITION. 

 Each Key Employee who receives an ISO
must agree to notify the Company in writing immediately after the Key Employee makes a Disqualifying Disposition of any shares acquired pursuant to the exercise of an ISO. A Disqualifying Disposition is any disposition (including any sale) of such
shares before the later of (a) two years after the date the Key Employee was granted the ISO, or (b) one year after the date the Key Employee acquired Shares by exercising the ISO. If the Key Employee has died before such stock is sold,
these holding period requirements do not apply and no Disqualifying Disposition can occur thereafter. 
  

	22.	TERMINATION OF THE PLAN. 

 The Plan will terminate on, the date which is ten
(10) years from the earlier of the date of its adoption and the date of its approval by the shareholders of the Company. The Plan may be terminated at an earlier date by vote of the shareholders of the Company. Notwithstanding the above, the
termination of the Plan shall not affect any Option Agreements or Stock Grant Agreements still in force as of the date of such termination, and the Plan shall remain in effect to the extent necessary to govern the terms of such agreements. 

 

	23.	AMENDMENT OF THE PLAN AND AGREEMENTS. 

 The Plan may be amended by the shareholders of
the Company. The Plan may also be amended by the Administrator, including, without limitation, to the extent necessary to qualify any or all outstanding Stock Rights granted under the Plan or Stock Rights to be granted under the Plan for favorable
federal income tax treatment (including deferral of taxation upon exercise) as may be afforded incentive stock options under Section 422 of the Code, and to the extent necessary to qualify the shares issuable upon exercise or acceptance of any
outstanding Stock Rights granted, or Stock Rights to be granted, under the Plan for listing on any national securities exchange or quotation in any national automated quotation system of securities dealers. Any amendment approved by the
Administrator which the Administrator determines is of a scope that requires shareholder approval shall be subject to obtaining such shareholder approval. Any modification or amendment of the Plan shall not, without the consent of a Participant,
adversely affect his or her rights under a Stock Right previously granted to him or her. With the consent of the Participant affected, the Administrator may amend outstanding Option Agreements and Stock Grant Agreements in a manner which may be
adverse to the Participant but which is not inconsistent with the Plan. In the discretion of the Administrator, outstanding Option Agreements and Stock Grant Agreements may be amended by the Administrator in a manner which is not adverse to the
Participant. 

  
 Page 15 of 19 

	24.	EMPLOYMENT OR OTHER RELATIONSHIP. 

 Nothing in this Plan or any Option Agreement or Stock
Grant Agreement shall be deemed to prevent the Company or an Affiliate from terminating the employment, consultancy or director status of a Participant, nor to prevent a Participant from terminating his or her own employment, consultancy or director
status or to give any Participant a right to be retained in employment or other service by the Company or any Affiliate for any period of time. 
  

	25.	RESTRICTION ON ISSUE OF SHARES. 

 (a) Notwithstanding the provisions of Paragraph 8, the
Company may delay the issuance of Shares covered by the exercise of an option and the delivery of a certificate for such Shares until the delivery or distribution of any shares issued under this Plan complies with all applicable laws (including
without limitation, the Securities Act of 1933, as amended), and with the applicable rules of any stock exchange upon which the shares of the Company are listed or traded. 

(b) It is intended that all exercises of options shall be effective, and the Company shall use its best efforts to bring about compliance with
all applicable legal and regulatory requirements within a reasonable time, except that the Company shall be under no obligation to qualify Shares or to cause a registration statement or a post-effective amendment to any registration statement to be
prepared for the purpose of covering the issue of Shares in respect of which any option may be exercised, except as otherwise agreed to by the Company in writing. 
  

	26.	RESERVATION OF STOCK. 

 The Company shall at all times during the term of the Plan
reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of the Plan and shall pay all fees and expenses necessarily incurred by the Company in connection therewith. 

 

	27.	NOTICES. 

 Any communication or notice required or permitted to be given under the Plan
shall be in writing, and mailed by registered or certified mail or delivered by hand, if to the Company, to its principal place of business, attention: Secretary, and, if to a Participant, to the address as appearing on the records of the Company.

  

	28.	GOVERNING LAW. 

 This Plan shall be construed and enforced in accordance with the law of
the Commonwealth of Massachusetts. 
  

	29.	APPROVAL OF STOCKHOLDERS. 

 The Plan shall be subject to approval by the vote of
stockholders holding at least a majority of the voting stock of the Company present, or represented, and entitled to vote at a duly held stockholders’ meeting, or by written consent of the stockholders as provided for under

  
 Page 16 of 19 

 
applicable state law, within twelve (12) months after the adoption of the Plan by the Board of Directors and shall take effect as of the date of adoption by the Board of Directors upon such
approval. The Committee may not grant Stock Rights under the Plan prior to such approval. 
 Adopted by the Board of Directors on September
12, 2006. 
 Amended by the Board of Directors on: November 12, 2007 (amendment No. 1), March 14, 2008 (amendment No. 2), June 18, 2009
(amendment No. 3), April 1, 2010 (amendment No. 4), January 31, 2011 (amendment No. 5), August 12, 2011 (amendment No. 6), February 15, 2012 (amendment No. 7), January 31, 2013 (amendment No. 8), March 31, 2014 (amendment No. 9) and April 14, 2014
(amendment No. 10). 
 Adopted by the Stockholders on October 30, 2006. 

Amendments approved by the Stockholders on: November 14, 2007 (amendment No. 1), March 14, 2008 (amendment No. 2), June 19, 2009 (amendment No.
3), April 1, 2010 (amendment No. 4), January 31, 2011 (amendment No. 5), August 12, 2011 (amendment No. 6), February 24, 2012 (amendment No. 7), January 31, 2013 (amendment No. 8), March 31, 2014 (amendment No. 9) and April 14, 2014 (amendment No.
10). 

  
 Page 17 of 19 

 EXHIBIT A 

DEFINITIONS 
 “Administrator” means the
Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the Administrator means the Committee. 

“Affiliate” means a corporation which, for purposes of Section 424 of the Code, is a parent or subsidiary of the Company, direct or
indirect. 
 “Board of Directors” means the Board of Directors of the Company. 

“Code” means the United States Internal Revenue Code of 1986, as amended, and all rules and regulations promulgated thereunder by the
regulatory agencies with authority thereunder. 
 “Committee” means the committee of the Board of Directors to which the Board of Directors
has delegated power to act under or pursuant to the provisions of the Plan. 
 “Common Stock” means shares of the Company’s common
stock without par value. 
 “Company” means Ocular Therapeutix., Inc. a Delaware corporation. 

“Disability” or “Disabled” means permanent and total disability as defined in Section 22(e)(3) of the Code. The
Administrator shall make the determination both of whether Disability has occurred and the date of its occurrence (unless a procedure for such determination is set forth in another agreement between the Company and such Participant, in which case
such procedure shall be used for such determination). If requested, the Participant shall be examined by a physician selected or approved by the Administrator, the cost of which examination shall be paid for by the Company. 

“Fair Market Value” of a Share of Common Stock means: 

(1) If the Common Stock is listed on a national securities exchange or traded in the over-the-counter market and sales prices are regularly
reported for the Common Stock, the closing or last price of the Common Stock on the Composite Tape or other comparable reporting system for the trading day immediately preceding the applicable date; 

(2) If the Common Stock is not traded on a national securities exchange but is traded on the over-the-counter market, if sales prices are not
regularly reported for the Common Stock for the trading day referred to in clause (1), and if bid and asked prices for the Common Stock are regularly reported, the mean between the bid and the asked price for the Common Stock at the close of
trading in the over-the-counter market for the trading day on which Common Stock was traded immediately preceding the applicable date; and 

(3) If the Common Stock is neither listed on a national securities exchange nor traded in the over-the-counter market, such value as the
Administrator, in good faith, shall determine. 
 “ISO” means an option meant to qualify as an incentive stock option under
Section 422 of the Code. 

  
 Page 18 of 19 

 “Key Employee” means an employee of the Company, an Affiliate or a Strategic Partner (including,
without limitation, an employee who is also serving as an officer or director of the Company or of an Affiliate), designated by the Administrator to be eligible to be granted one or more Stock Rights under the Plan. 

“Non-Qualified Option” means an option which is not intended to qualify as an ISO. 

“Option” means an ISO or Non-Qualified Option granted under the Plan. 

“Option Agreement” means an agreement between the Company and a Participant delivered pursuant to the Plan, in such form as the Administrator
shall approve. 
 “Participant” means a Key Employee, director or consultant of the Company or its Affiliates to whom one or more Stock
Rights are granted under the Plan and who are eligible to participate in this Plan under Paragraph 2. As used herein, “Participant” shall include “Participant’s Survivors” where the context requires. 

“Plan” means this 2006 Stock Incentive Plan. 

“Shares” means shares of the Common Stock as to which Stock Rights have been or may be granted under the Plan or any shares of capital stock
into which the Shares are changed or for which they are exchanged within the provisions of the Plan. 
 “Stock Grant” means a grant by the
Company of Shares under the Plan also means the grant by the Company of a right to purchase Shares under a restricted stock purchase arrangement on terms that the Administrator deems appropriate. 

“Stock Grant Agreement” means an agreement between the Company and a Participant delivered pursuant to the Plan, in such form as the
Administrator shall approve. 
 “Stock Right” means a right to Shares of the Company granted pursuant to the Plan under an ISO, a
Non-Qualified Option or a Stock Grant. 
 “Strategic Partners” means any contractor, joint venture partner or other entity having a
relationship with the Company, which relationship the Administrator, at its discretion, determines will promote the success of the Company. 

“Survivors” means a deceased Participant’s legal representatives and/or any person or persons who acquired the Participant’s rights
to a Stock Right by will or by the laws of descent and distribution. 

  
 Page 19 of 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]